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SUMMARY 
 
Owing to the development of nanotechnology and biotechnology, nanoparticles of 
biodegradable polymers as effective drug delivery systems have received significant 
attention. They have the ability to carry various therapeutic agents including 
anticancer drugs, DNA, peptides and proteins. Among various FDA-approved 
biodegradable polymers, poly(lactide acid) (PLA), poly(lactide-co-glycolide) (PLGA) 
and poly(ε-caprolactone) (PCL) are most oftenly used in these areas. However, most 
of them have not been able to meet these demands due to their hydrophobic nature. 
They are not biocompatible with hydrophilic drugs. Biodegradable block copolymers 
with better hydrophobic and hydrophilic balance thus are desired and this can be done 
by inserting hydrophilic elements into the hydrophobic chains of the polymers. In the 
thesis, d-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or simply 
TPGS), which is actually a PEGylated vitamin E was introduced into the hydrophobic 
polymer backbone of PLA and PLGA to form PLA-TPGS and PLGA-TPGS block 
copolymers. These block copolymers are an example of amphiphiles. Their uses as 
different carriers for delivery of protein and anticancer drug and as targeted agents for 
target specific delivery were addressed in this thesis.  
 
Poly(lactide) – tocopheryl polyethylene glycol (PLA-TPGS) copolymers with various 
PLA:TPGS ratios were synthesized. Nanoparticles of PLA-TPGS were prepared by 
double emulsion method for protein drug formulation with bovine serum albumin 
(BSA) as a model protein. Influence of the PLA:TPGS component ratio and the BSA 
loading level on the drug encapsulation efficiency (EE) and in vitro drug release 
behavior were investigated. The proteins released from the PLA-TPGS nanoparticles 
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retained good structural integrity for at least 35 days at 37 oC as indicated by SDS-
PAGE and circular dichroism (CD) spectroscopy. Confocal laser scanning microscopy 
(CLSM) observation demonstrated the intracellular uptake of the PLA-TPGS 
nanoparticles by NIH-3T3 fibroblast cell and Caco-2 cancer cell. This research 
suggests that PLA-TPGS nanoparticles could be of great potential for clinical 
formulation of proteins and peptides. 
 
Vitamin E TPGS-folate (TPGS-FOL) conjugate and doxorubicin-poly(lactide-co-
glycolide)-vitamin E TPGS (DOX-PLGA-TPGS) conjugate were synthesized. DOX-
loaded nanoparticles composed of TPGS-FOL and DOX-PLGA-TPGS conjugates 
with various blend ratios were prepared by solvent extraction/evaporation method for 
targeted chemotherapy of folate-receptor rich tumors.  X-ray photoelectron 
spectroscopy (XPS) demonstrated that folate was distributed on the nanoparticle 
surface while the drug molecules were entrapped in the core of the nanoparticles. The 
nanoparticles were found to be ~350 nm size and exhibited a biphasic pattern of in 
vitro drug release over 4 weeks. The cellular uptake and cell viability of the two types 
of DOX-loaded nanoparticles were investigated by using MCF-7 breast cancer cell 
line and C6 glioma cell line, which were found to be dependent on the content of 
targeting TPGS-FOL. These results suggest that our novel TPGS-FOL decorated 
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 CHAPTER 1  INTRODUCTION 
 
1.1 General background 
Despite that PLA and PLGA have been extensively investigated for drug delivery 
(Chauhan et al., 2004), there are still a lot of efforts in designing new block 
copolymers to match the hydrophobic and hydrophilic properties. Block copolymers 
are examples of amphiphiles where the amphiphilic behaviour, mechanical and 
physical properties can be manipulated by adjusting the ratio of the constituting block 
or adding new blocks of desired properties (Kumar et al., 2001). Some successful 
examples of block copolymers include poly(ester)-block-poly(ether) and poly(ether 
ester amide). Among poly(ester)-block-poly(ether) block copolymers, many efforts 
have been made to form block copolymers comprising PLA and polyethylene glycol 
(PEG) (Kimura et al., 1989; Deng et al., 1995; Xiong et al., 1995; Dong and Feng, 
2004). PEG is an excellent biocompatible biomaterial due to its flexibility, non-
toxicity, hydrophilicity and stealth properties. Lately, Zhang and Feng (2006a) have 
developed a new family of block copolymers comprising PLA and TPGS. TPGS is a 
water-soluble derivative of natural vitamin E, which has amphiphilic structure 
comprising a tocopherol (vitamin E) hydrophobic group and a PEG hydrophilic group. 
Its bulky structure and large surface area make it to be an excellent emulsifier, 
solubilizer, bioavailability enhancer of hydrophobic drugs (Traber et al., 1994). TPGS 
can also enhance the oral bioavailability of anticancer drugs by improving the 
solubilization or emulsification of the drug in the finished dosage form and/or through 
formation of a self-emulsifying drug delivery system in the stomach. This is because 
TPGS can improve drug permeability across cell membranes by inhibiting P-
glycoprotein, thus enhancing absorption of a drug through the intestinal wall and into 
  1 
 the bloodstream (Dintaman and Silverman, 1999; Rege et al., 2002; Bogman et al., 
2003; Bogman et al., 2005). TPGS has been found as a good emulsifier and additive in 
micoparticles and nanoparticles fabrication. High drug entrapment efficiency and high 
emulsification efficiency can be achieved as compared to PVA (67-times higher than 
PVA) (Mu and Feng, 2003). TPGS-emulsified, drug-loaded PLGA nanoparticles have 
shown higher drug encapsulation and cellular uptake, longer half life and higher 
therapeutic effects of formulated drug than those emulsified by poly(vinyl alcohol) 
(PVA), a conventional emulsifier in nanoparticle technology (Mu and Feng, 2002; 
2003; Feng et al., 2004; Khin and Feng, 2005; Khin and Feng, 2006).  
 
Recently, many studies on the use of blends and copolymerization of PLA or PLGA 
with PEG for peptide/protein drugs delivery have been undertaken (Peracchia et al., 
1997; Quellec et al., 1998; Cho et al., 2001; Ruan et al., 2003; Zhou et al., 2003). 
Generally, the difference of hydrophilic drugs, such as peptides and proteins, in 
physico-chemical properties with hydrophobic PLA or PLGA matrix has profound 
consequence on the protein encapsulation efficiency during preparation procedure, 
protein stability during manufacture, storage and release process. This becomes a 
constraint for their use in protein drugs delivery. The introduction of PEG into the 
PLA or PLGA backbone could increase the hydrophilicity of the polymer matrix by 
creating a swollen hydrogel-like environment (Bittner et al., 1999). PLA-PEG-PLA or 
PLGA-PEG-PLA copolymeric microspheres have been shown to provide a controlled 
release for a period time of 2 to 3 weeks (Bittner et al., 1999; Witt et al., 2000). PLA-
TPGS copolymer may provide an alternative approach for sustained and controlled 
protein delivery. The amphiphilic domain of PLA-TPGS copolymer is believed to act 
as a protein stabilizer or surface modifier of the hydrophobic PLA network, to 
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 promote the stability of proteins, increase the protein loading efficiency and decrease 
the amount of emulsifier used in PLA-TPGS nanoparticle preparation.  
 
In addition to protein drugs delivery, block copolymers composed of hydrophilic and 
hydrophobic domains have also been studied extensively in the anticancer drug 
delivery as an alternative drug carrier since last decade (Shin et al., 1998; Jeong et al., 
1999; Ryu et al., 2000; Kim and Lee, 2001; Lee et al., 2003; Potineni et al., 2003; 
Dong and Feng, 2004; Zhang and Feng, 2006b). These copolymeric carriers have been 
used to encapsulate hydrophobic and hydrophilic anticancer drugs, to increase blood 
circulation time and decrease the liver uptake of nanoparticles. For instance, the PEG-
modified PLGA nanoparticles which prepared mostly by using a diblock copolymer of 
PLGA-PEG have been demonstrated to prolong their half-life in the circulation due to 
presence of highly mobile and flexible PEG chains on the surface (Gref et al., 2000). 
Nevertheless, these PEG-modified PLGA nanoparticles could not be delivered to the 
specific cancer cells in a target-specific manner. In order to enhance the intracellular 
delivery capacity of polymeric nanoparticles to specific cells, the most widely used 
approach is attaching cell recognizable targeting ligands, such as monoclonal 
antibodies, endogenous targeting peptides and low molecular weight compounds like 
folate (vitamin folic acid), onto the surface of the nanoparticles (Bellocq et al., 2003; 
Faraasen et al., 2003; Gao et al., 2004). Among them, folate has been widely used as 
targeting moiety for delivering anticancer drugs within cells via receptor-mediated 
endocytosis (Sudimack and Lee, 2000; Lee et al., 2002; Saul et al., 2003; Yoo and 
Park, 2004a). Our group previously demonstrated that PLA-TPGS nanoparticles for 
paclitaxel formulation have shown great advantages over Taxol and the PVA-
emulsifier PLGA nanoparticles formulation for oral delivery (Zhang and Feng, 2006b; 
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 2006c). We hence aimed at designing a convenient cancer-specific drug delivery 
system for biodegradable PLGA-TPGS nanoparticles by utilizing novel surfactant, 
which is TPGS-folate (TPGS-FOL) conjugate. TPGS-FOL has dual functions of being 
a surfactant as well as a targeting ligand in our nanoparticulate delivery system. 
 
 
1.2 Objective and thesis organization 
From this introduction, we can see that nanoparticles of biodegradable copolymers are 
very important in the area of drug delivery to achieve excellent therapeutic effects. As 
mentioned before, nanoparticles of PLA-TPGS copolymers possess great potential for 
oral delivery of anticancer drugs (Zhang and Feng, 2006b; 2006c). The developmental 
work of this copolymer is still needed, especially for the application in protein drug 
delivery and targeted drug delivery. The objective and scope of this thesis are 
illustrated below. 
  
The body of this thesis is made up of six chapters. Chapter 1 gives a brief introduction 
to the project as well as the objective of the project. Chapter 2 is a literature review on 
the topics related to the project. In Chapter 3, the materials and methods used in all 
experiments are outlined. In Chapter 4, we aim to develop PLA-TPGS nanoparticles 
for controlled delivery of peptides and proteins with BSA as a model protein. In 
Chapter 5, we design a convenient targeted drug delivery system for biodegradable 
PLGA-TPGS nanoparticles by decorating the nanoparticles with a novel surfactant, 
TPGS-FOL, which has dual functions of being a surfactant and a targeting ligand in 
the nanoparticulate delivery system. Lastly, in Chapter 6, an overall conclusion is 
  4 
 given and the suggestions for future work on the study and preparation of 
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 CHAPTER 2 LITERATURE REVIEW 
 
2.1 Nanoparticles of biodegradable polymers for drug delivery 
2.1.1 Nanoparticles drug delivery systems 
Over the past few decades, much effort has been devoted to developing 
nanotechnology for drug delivery because of its suitability and feasibility in delivering 
small molecular weight drugs, as well as macromolecules such as proteins, peptides or 
genes by either localized or targeted delivery to the tissue or cell of interest (Moghimi 
et al., 1991; Saltzman et al., 2003).  
 
Nanoparticles generally vary in size from 10 to 1000 nm. Polymeric nanoparticles for 
drug delivery systems are defined as submicron-sized (< 1 µm) colloidal systems 
made of solid polymers (biodegradable or not) (Panyam et al., 2003). The therapeutic 
agent of interest may be either entrapped within the polymer matrix or absorbed onto 
the surface of particles, depending upon the process used for the preparation of 
nanoparticles, nanospheres or nanocapsules. Nanospheres are matrix systems in which 
the drug is physically and uniformly dispersed throughout the particles. On the other 
hands, unlike nanospheres, nanocapsules are vesicular systems in which drug is 
confined within a liquid inner core that surrounded by a unique polymeric wall 
(Courvreur et al., 1996).  Polymeric nanoparticles hence can be classified as shown in 















Nanosphere Nanosphere (prepared by double 
emulsion technique)
Nanocapsule






Fig. 2-1 Different types of polymeric nanoparticles: (a) entrapped drug, (b) adsorbed 




The nanometer size-ranges of the above mentioned delivery systems offer distinct 
advantages for drug delivery over microparticles (> 1 µm). The sub-micron and sub-
cellular size of the nanoparticles enable them to penetrate deep into tissues through 
fine capillaries, cross the fenestration present in the epithelial lining such as liver and 
are generally taken up efficiently by the cells (Vinogradov et al., 2002). It was 
demonstrated in previous studies that 100 nm size nanoparticles showed 2.5-fold 
greater uptake compared to 1 µm and 6-fold higher uptake compared to 10 µm 
microparticles in Caco-2 cell line (Desai et al., 1997) as well as 15-250-fold greater 
efficiency of uptake than larger size (1 and 10 µm) microparticles in a rat in situ 
intestinal loop model (Desai et al., 1997). Besides, nanoparticles can have a further 
advantage over larger microparticles in term of administration (especially for 
intravenous delivery) into systemic circulation without the problems of particles 
aggregation and embolism formation. It is because the smallest capillaries in the body 
  7 
 are 5-6 µm in diameter. In order for the particles to be distributed into the bloodstream 
without any blockage of fine blood capillaries, the particles size has to be significantly 
smaller than 5 µm or preferably in nanometer ranges (Chansiri et al., 1999; Hans and 
Lowman, 2002). 
 
2.1.2 Biodegradable polymers 
The term “biodegradable polymers” denotes natural or synthesized macromolecules 
which are biocompatible with human body and degradable under physiological 
condition into harmless byproduct (Fu et al., 2000). Biodegradable polymers will 
contain hydrolysable functional groups directly in the polymer chain. As these groups 
in the chain are hydrolyzed, the polymer chain is slowly reduced to shorter and shorter 
chain segments which eventually become water-soluble (Dunn, 1990). 
 
A number of different polymers, both synthetic and natural, have been employed in 
formulating biodegradable nanoparticles (Moghimi et al., 1991). However, as 
compared to synthetic polymers, natural polymers have not been widely used for this 
purpose because they are not only inconsistent in purity, but also frequently involve in 
cross-linking that could denature the encapsulated drug (Chansiri et al., 1999). In 
contrast, synthetic polymers have the advantage of sustaining the release of the 
encapsulated therapeutic agent over a period of days up to several weeks compared to 
natural polymers which only have a relatively short duration of drug release.  
 
The polymers used for the formulation of nanoparticles include synthetic polymers 
such as polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolides) 
(PLGA), polycaprolactone (PCL) and polyorthoesters (POE) as well as natural 
  8 
 polymers such as albumin, gelatin, collagen and chitosan. Of these polymers, PLA and 
PLGA have been the most extensively studied polymers for drug delivery (Peracchia 
et al., 1997; Chauhan et al., 2004). Although these polyester based 
polymers/copolymers were originally used as absorbable suture materials (Feng, 
2006), they are well-known for their biocompatibility and resorbability through 
normal metabolism pathways. They undergo hydrolysis upon implantation into the 
body, forming biologically compatible and metabolizable moieties such as lactic acid 
and glycolic acid. These acids are eventually reduced by the Kreb’s cycle to carbon 
dioxide and water, which can be easily expelled by the body. Polymer biodegradation 
products should not have any adverse reactions within biological environment because 
they are formed at a very slow rate (Panyam et al., 2003). 
 
2.1.3 Nanoparticles fabrication methods 
Nanoparticles have been mainly prepared either by the dispersion of the preformed 
polymers or by polymerization of monomers (Soppimath et al., 2001). For dispersion 
of the preformed polymers, several methods have been suggested to prepare 
biodegradable polymeric nanoparticles such as solvent extraction/evaporation method, 
nanoprecipitation method, dialysis method and spray-drying method. 
 
2.1.3.1 Solvent extraction/evaporation method 
Solvent extraction/evaporation method (or single emulsion method) is the most 
common method for preparing solid, polymeric nanoparticles. In this method, an 
organic mixture of polymer and drug is emulsified in an aqueous solution with 
surfactant or emulsifying agent such as PVA, poloxamer 188, gelatin or TPGS to 
make an oil-in-water (o/w) emulsion. The nanosized polymer droplets are usually 
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 induced by sonication or homogenization. After that, organic solvent used such as 
DCM (dichloromethane) was evaporated and nanoparticles are collected by 
centrifugation and lyophilization. For this fabrication method, the drug has to be at 
least partially soluble in organic solvent in order to be encapsulated. This method has 
been successful for encapsulating hydrophobic drugs, but has poor results in 
encapsulating therapeutic agents of a hydrophilic nature such as hydrophilic 
anticancer drugs, proteins, peptides and DNA. Fig. 2-2(a) shows the particle 
preparation methods by single emulsion method. 
 
 
Fig. 2-2(a) Schematic diagram of single emulsion method. 
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Fig. 2-2(b) Schematic diagram of double emulsion method. 
 
Double emulsion method is a modified method on the procedure of single emulsion 
method in order to favor the encapsulation of hydrophilic compounds. This method 
enabled hydrophilic compounds to be partitioned into aqueous phase and hence 
decreases the contact between the organic phase and the hydrophilic compounds, 
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 thereby improving the drug encapsulation efficiency. Briefly, an aqueous solution of 
the hydrophilic compound is first emulsified into an organic solution of polymer to 
form primary water-in-oil (w/o) emulsion. This primary w/o emulsion is then poured 
into a large volume of water with surfactant or emulsifying agent to form multiple 
water-in-oil-in-water (w/o/w) emulsion (Zambaux et al., 1998). From here, the 
procedure for obtaining nanoparticles is similar to that of single emulsion method. Fig. 
2-2(b) shows the particle preparation procedure by double emulsion method. 
 
2.1.3.2 Nanoprecipitation method 
Nanoprecipitation (interfacial deposition) method was developed by Fessi et al (1989). 
This method is sometimes referred as spontaneous emulsification/solvent diffusion 
method in some literature. In this modified version of the solvent evaporation method, 
the preformed polymer and drug are dissolved into water-soluble solvent such as 
acetone, acetonitrile or methanol. This organic phase is then added dropwise to the 
aqueous phase. Pluronic F-68, a polyoxyethylene-polyoxypropylene triblock 
copolymer, is widely used as surfactant in the nanoprecipitation method. An 
interfacial turbulence will be created from the spontaneous diffusion of water-soluble 
solvent to water, leading to the formation of nanoparticles. The surfactant used in this 
process is not directly involved in the formation of nanoparticles. Instead, its function 
is to keep good steric stability of the formed nanoparticles (Dong and Feng, 2004). 
Nanoprecipitation method has distinct advantages such as (a) minimize or avoid the 
usage of potentially toxic components including chlorinated solvents and surfactant, 
and (b) smaller particles size (sub-200 nm) with narrow size distribution can be 
reproduced without external energy (Chorny et al. 2002; Dong and Feng, 2004). 
However, a major drawback of this technique is the difficulty in choosing a 
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 drug/polymer/solvent/nonsolvent system in which the nanoparticles can be formed 
without aggregation and the drug can be efficiently entrapped (Allemann et al. 1993). 
Besides, it is not an efficient method to encapsulate water-soluble drugs either.  
 
2.1.3.3 Dialysis method  
Dialysis method is simple but effective preparation method for preparing surfactant-
free nanoparticulate system. A surfactant-free nanoparticulate system not only has the 
advantages in ease of preparation, but also preventing the possible side effects of 
surfactant on the human body. Surfactant or emulsifier that required for stabilizing the 
dispersed oil droplets in conventional solvent extraction/evaporation method are 
present on the surface of particles. Almost all of these nanoparticle surface-located 
surfactants are non-biodegradable, non-digestable and non-biocompatible. They can 
be harmful to human body by allergy-like reactions (Jeong et al., 2001; Jeong et al., 
2003). 
 
For this method, polymer and drug are firstly dissolved in water-miscible solvent such 
as DMF, DMSO or THF. The solution is then transferred into a dialysis membrane 
with certain molecular cut-off and dialyzed against large volume of deionized water 
for about two days to remove free drug and organic solvent. In dialysis system, 
solvent systems used to prepare nanoparticles are strictly limited to water-miscible 
solvents which can dissolve both the polymer and drug well. This is because water-
immiscible solvent such as DCM and chloroform cannot diffuse out or evaporate from 
the dialysis membrane to the outer aqueous environment. The solubility and 
miscibility between the polymer and solvent or the water and solvent or viscosity of 
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 the solvent itself may play a significant role in determining the particle size 
distribution (Jeong et al., 2001).  
 
2.1.3.4 Supercritical fluid spraying method 
Another way of preparing particles from a preformed polymer is supercritical fluid 
spraying method, and it is an emerging technique for preparing the particles without 
the use of any toxic organic solvent and surfactant. Thus, it is a more environmental 
friendly method for the production of drug-loaded sub-micron particles (Mawson et 
al., 1995; Soppimath et al., 2001; Feng and Chien, 2003). Basically, the drug and 
polymer is solubilized in a supercritical fluid and then the solution is expanded 
through a nozzle. The supercritical fluid will undergo evaporation during spraying 
process and the solute will eventually precipitate. Unfortunately, this technique is less 
of practical interest mainly due to the fact that most of the polymers exhibit limited 
solubility in the supercritical fluid (Soppimath et al., 2001).  
 
2.1.3.5 Polymerization method 
Besides synthesis from the biocompatible polymers, it is possible to prepare 
nanoparticles from monomers or macromonomers by polycondensation reactions 
(polymerization of monomers) (Behan et al., 2001; Soppimath et al., 2001). 
Polymerization includes emulsion polymerization and interfacial polymerization. 
Emulsion polymerization builds up a chain of polymers from single monomers. The 
polymerization process is initiated by radical or ion formation. The residual monomers 
are always removed by filtration in this case. The drug of interest can be attached onto 
the surface of nanoparticles by adsorption. For interfacial polymerization, monomer-
contained organic phase and aqueous phase are brought together by mechanical force. 
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 Drug is dissolved in the polymerization medium either before the addition of 
monomer or at the end of the polymerization reaction. The nanoparticles suspension is 
then purified by ultracentrifugation.  
 
 
2.2 Peptide and protein drug delivery 
2.2.1 Structural aspect of peptide/protein 
Proteins are the most abundant components of cells which exist as enzymes, 
antibodies, hormones, transport mediators and also structural components for the 
skeleton of the cell itself (Zubay, 1983). They are an integral part of the body as they 
carry out all important physiological and biological processes like ligands for 
signaling, enzymes for biotransformation reactions, receptors for pharmacological 
response elucidation, antibodies in immune system interactions, transcription and 
translation (Sinha and Trehan, 2003).  
 
Proteins are the most functionally diverse of all biological substances although all the 
proteins are constructed from the same 20 amino acids (Banga and Chien, 1988). They 
are macromolecules with molecular weights ranging from approximately 5,000 to 
several millions. Each protein molecule is a polymer with α-amino acids linked 
together in sequential manner by peptide bonds (covalent bond that formed by the α-
carboxyl and α-amino groups of the adjacent amino acid residues). The resulting 
polymers are called peptides. Peptides that contain about eight or more amino acids 
are called polypeptides, while polypeptides that contain from about 50 to as many as 
2,500 amino acids are called protein (Zubay, 1983; Banga and Chien, 1988). 
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The polypeptide chain of a protein is folded into a specific three-dimensional 
structure, which is referred to as the conformation of the protein. Actually, proteins 
have several levels of structure (Fig. 2-3) and the general term “conformation” only 
refers to these structures in combination. A protein molecule has a primary structure, 
which refers to covalent backbone of the polypeptide chain and the sequence of its 
amino acid residues; a secondary structure, which refers to a regular, recurring 
arrangement in space of the polypeptide chain along one dimension; a tertiary 
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 structure, which refers to how the polypeptide chain is bent or folded in three 
dimension to form the compact, tightly folded structure of globular proteins, and a 
quaternary structure, which refers to how individual polypeptide chains of a protein 
having two or more chains are arranged in relation to each other (Zubay, 1983; Banga 
and Chien, 1988). 
 
2.2.2 Challenges in peptide/protein drug delivery 
The therapeutic use of peptide and protein drugs has been popularized in the last 
decade following the recent development of numerous recombinant protein drugs such 
as hormones and vaccines (Cohen et al., 1991). This new class of therapeutic agents 
can treat a broad range of ailments such as cancer, autoimmune diseases, memory 
impairment, hypertension, mental disorder, certain cardiovascular and metabolic 
diseases (Banga and Chien, 1988). Despite many attractive features that proteins have 
as therapeutic agents, they have some serious limitations. For instance, due to 
proteins’ instability, high molecular weight, hydrophilicity, complexity in structure 
and poor permeability, they have very challenging task in their delivery. One of the 
main barriers to successful delivery of proteins is enzymatic barriers and absorption 
barriers imposed by gastrointestinal tract (Sinha and Trehan, 2003). There are several 
of enzymes such as gastric proteases and pancreatic proteases in gastrointestinal tract 
which can cause protein degradation. Proteins’ hydrophilic nature and large molecular 
size also cause them to have poor intrinsic permeability across biological membranes. 
Complexity of protein structure plays a very important role in affecting delivery and 
biological effectiveness. Proteins must maintain their specific, folded, three-
dimensional structure (conformation) through all formulation steps of delivery 
systems and while the drug is released from dosage form at the site of delivery so that 
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 their biological activity are retained. In addition, peptides and proteins possess labile 
bonds and side chains with chemically reactive group. Disruption of their structure or 
modifications of the side chain are easily occurred in many proteins. They can easily 
undergo non-chemical changes like folding and unfolding, which lead to loss of native 
structure and result in interaction with surroundings by adsorbing to surfaces or 
aggregating with other protein molecules (Manning et al., 1989). 
 
2.2.3 Approaches for delivery of peptide/protein drugs 
2.2.3.1 Parenteral delivery 
Due to the poor absorption and low bioavailability by all non-parenteral routes for 
effective systemic delivery of peptide/protein drugs, peptide/protein drugs are 
preferably administered by parenterally. For parenteral administration, major routes 
are by intravenous (i.v.) intramuscular (i.m.) and subcutaneous (s.c.) injections (Sinha 
and Trehan, 2003; Pawar et al., 2004). However, multiple injections are required to 
achieve therapeutic effectiveness. It is because of the short half life of proteins 
injected parenterally. The unavoidable frequent dosing will be not only a tedious 
procedure but also cause discomfort to the patients.  
 
2.2.3.2 Oral delivery 
Poor permeation across the biological barriers like intestinal lumen has been the main 
hurdle with oral delivery of peptide/protein drugs. Besides, peptide/protein drugs 
which are given orally will be degraded by the strong acidic environment and 
proteolytic enzymes from the gastric and intestinal fluid. As a result, they do not reach 
intact the site of absorption. Generally, peptide/protein drugs have low oral 
bioavailabilities (< 1-2%) and short in vivo half lives (<30 min) (Zhou, 1994). 
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 2.2.3.3 Other non-parenteral delivery 
Other non-parenteral administration routes for delivery of peptide/protein drugs 
include the nasal, buccal, rectal, vaginal, transdermal, ocular and pulmonary routes. 
However, these routes are relatively less effective than parenteral administration in the 
absence of an absorption-promoting adjuvant. Various absorption enhancers like 
surfactants, bile acids, enamine derivatives, sodium salicylate have been used to 
enhance adsorption of proteins (Banga and Chien, 1988). 
 
2.2.3.4 Biodegradable particles as delivery system 
Despite that parenteral delivery of proteins by biodegradable particles is the most 
suitable and preferred delivery routes till today (Ogawa et al., 1988; Sinha and Trehan, 
2003), polymeric particles has emerged as an exciting approach to enhance the uptake 
and transport of orally administered proteins. Polymeric particles will isolate the 
encapsulated proteins from external medium, therefore protecting them from various 
proteolytic enzymes and being uptaken by enterocytes. After absorption, polymeric 
particles will slowly degrade following a kinetic profile that depends on the nature of 
polymer as well as providing a controlled and sustained release of peptide/protein 
drugs (Prokop et al., 2002; Vila et al., 2002). 
 
 
2.3 Anticancer drug delivery 
2.3.1 Cancer, cancer causes and cancer treatment 
Cancer is a leading cause of death and has become the number one killer in many 
countries, including in Singapore. Even though great efforts were being made, no 
substantial progress has been observed over the past 50 years in treating cancer. The 
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 cancer death rate in USA was 1.939% of the total population in 1950. It was still 
1.940% in 2001, 1.934% in 2002 and 1.901% in 2003 (Feng, 2006). This observation 
hence shows the inefficiency of the progress in cancer treatment.  
 
Cancer is caused by uncontrolled growth and spreading of abnormal cells. It can 
seriously threaten human health until lead to human mortality (Feng and Chien, 2003). 
Cancer is usually developed in the form of tumors. Once a small tumor mass has 
formed, the normal tissue will not be able to compete with the cancer cells for 
adequate supply of nutrients from the blood stream. Tumor cells will hence continue 
to divide and expand. The exact molecular mechanisms that stimulate angiogenesis at 
a tumor site are still not well understood. However, both external and internal factors 
are believed to be relevant. The external factors include tobacco smoking, alcohol 
usage, chemical exposure (benzene, aniline and asbestos), sun exposure, radiation and 
infections while the internal factors are inherited metabolism mutations, hormones and 
immune conditions. Both external and internal factors may act together or sequentially 
to initial and stimulate carcinogenesis (Feng and Chien, 2003). 
 
There are a few effective ways to treat cancer such as surgery, radiotherapy, 
chemotherapy, hormone therapy and  immunotherapy. Each of these treatment 
modalities has its own advantages and disadvantages. The surgical removal of 
cancerous tumor is widely used in treating cancers. However, it is very difficult for 
surgery to be thorough and it is unavoidable to have residual affected cells (Feng and 
Chien, 2003). Therefore, multimodal therapy that involves radiotherapy, 
chemotherapy, immunotherapy and other forms of treatments to follow surgery 
provides a chance to completely treat cancer.  
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 2.3.2 Cancer chemotherapy 
The general definition of chemotherapy refers to the use of any medicine for treatment 
of any disease in the literature or could mean “curing by chemicals” as given by Paul 
Ehrlich, the father of modern chemotherapy (Ehrlich, 1913). However, cancer 
chemotherapy is often understood in a narrower sense of treatment of cancer with 
drugs that can destroy cancer cells. These drugs are often called anticancer drugs 
(http://www.cancer.gov). Anticancer drug can inhibit the uncontrolled growth and/or 
multiplying of cancer cells. Depending on the type of cancer and how advanced it is, 
chemotherapy can be used for the purposes of relieving symptoms that the cancer may 
cause, controlling the cancer by slowing the cancer’s growth or curing the cancer.  
 
Many anticancer drugs are made to kill growing cells due to the reason that cancer 
cells may grow and divide rapidly than normal cells. However, in this case, normal 
cells can also be harmed, especially those that divide rapidly (http://www.cancer.gov). 
The damage to the normal healthy cells will cause various side effects such as fatigue, 
hair loss, anemia, kidney and bladder damage, constipation, infection, nausea and 
vomiting, diarrhea, mouth sores, depression etc. It is because fast-growing normal 
cells, such as blood cells forming in the bone marrow, cells in the digestive tract 
(mouth, stomach, intestine, esophagus), reproductive system (sexual organs) and hair 
follicles, cells of vital organs like heart, kidney, bladder, lungs and nervous system are 
affected by anticancer drugs. 
 
2.3.3 New-concept of chemotherapy 
In fact, the current regimen of chemotherapy is far from satisfactory. Nevertheless, 
nanoparticles of biodegradable polymers could be one of the most promising 
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 candidates to solve the problems in chemotherapy such as pharmacokinetics, drug 
toxicity and drug resistance with further development to promote new-concept of 
chemotherapy. According to Feng (2004), the new-concept of chemotherapy may 
include (i) sustained chemotherapy; (ii) controlled and targeted chemotherapy; (iii) 
personalized chemotherapy; (iv) chemotherapy across various physiological drug 
barriers such as the gastrointestinal (GI) barrier for oral chemotherapy and the blood-
brain barrier (BBB) for the treatment of brain cancer; and eventually (v) 
chemotherapy at home (i.e. with the available administrative routes that are 
manageable by patients themselves at home, such as oral delivery, nasal delivery and 
ocular delivery) (Feng, 2004; Feng, 2006).  
 
2.3.4 Targeted therapeutics in anticancer therapy 
Due to the therapeutic performance of anticancer drugs is often compromised by their 
low selectivity for cancer cells and unacceptable toxicity to normal tissues, targeted 
drug delivery systems become extremely important as it can optimize the therapeutic 
effect of anticancer drugs by increasing the drug concentration ratio of cancerous 
tissue to normal tissue. Drug targeting to a diseased tissue selectively not only will 
improve therapeutic efficiency but also enable a reduction of the amount of drug that 
have to be administered to achieve a therapeutic performance, therefore minimizing 
the negative side effects (Torchilin, 2000; Drotleff et al., 2004).  
 
Several approaches for improving the selective toxicity of anticancer therapeutics are 
being pursued at present. First, newer drugs are being developed to interfere with 
pathways, which are specifically activated in cancer cells such as signal-transduction 
pathways, tumor angiogenesis or downregulate proto-oncogenes that are involved in 
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 cancer cell proliferation. Examples of this type of new drug are limited except 
imatinib (Glivec), which targets the BCR-ABL oncogene that causes chronic 
myelogenous leukaemia and trastuzumab (Herceptin) that targets the HER2/neu 
(ERBB2) receptor for treating breast cancer (Brannon-Peppas and Blanchette, 2004). 
Nevertheless, these molecularly targeted therapies are still in early stage of their 
developmental work. 
 
Second, antibody- or ligand-mediated targeting of anticancer therapeutics is also being 
explored extensively. The basic principle of this ligand-targeted therapeutics is to 
deliver antineoplastic drugs to cancer-associated tissues selectively by associating the 
drugs with molecules that bind to antigens or receptors that are either uniquely 
expressed or overexpressed on the target cells relative to normal tissues (Lappi, 2002). 
This targeting approach can also be readily applied to drug carriers such as polymeric 
particles and liposomes. Advantages and disadvantages exist for each types of 
targeting moiety (both antibody and non-antibody ligands). Non-antibody ligands such 
as folate, transferrin, Arg-Gly-Asp tripeptide and Asn-Gly-Arg tripeptide, are often 
readily available, inexpensive to manufacture and easy to handle. However, their 
specificity for the target tissue may not be as good as monoclonal antibodies because 
of their promiscuities for different receptors (Lappi, 2002). On the other hand, 
monoclonal antibodies possess advantages of having a high degree of specificity for 
the target tissues and possibility of synergy between the signaling antibodies and the 
chemotherapeutics, because the cells will be targeted in two distinct ways (Seidman et 
al., 1995). However, their overall dimensions may cause them to diffuse poorly 
through biological barriers. In addition, they also remain expensive and time-
consuming to produce. 
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 2.3.5 Doxorubicin and its anticancer mechanism 
Doxorubicin is a type of anticancer drug called an “anthracyline glycoside”. It is 
sometimes also called as adriamycin or hydroxyldaunorubicin too. Fig. 2-4 shows the 
chemical structure of doxorubicin. The molecular formula of the doxorubicin is 
C27H29NO11 with molecular weight of 543.52 g/mol. Doxorubicin is a cytotoxic 
anthracycline antibiotic isolated from Streptomyces peucetius var. caesius 
(http://www.rxlist.com) and most commonly used in the treatment of lymphoma, 
osteosarcoma and other sarcomas, carcinomas and melanoma. Doxorubicin can be 
used alone or in combination with other cancer chemotherapy agents. Generic 













NO H2H  
Fig. 2-4 Chemical structure of doxorubicin. 
 
Similar to most of the anticancer drugs, doxorubicin is toxic to some normal cells 
because it attacks rapidly dividing cells. It is famous for “cumulative cardiotoxicity”.  
When the cumulative dose of doxorubicin reaches 450mg/m2, the patient’s heart 
becomes incapable of effective pumping and does not respond to therapy. Besides, 
others undesirable side effects include myelosuppression, decrease in white blood 
cells, nausea, hair loss and bone marrow toxicities (http://www.rxlist.com).  
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 Doxorubicin works by binding to DNA where it can inhibit the progression of the 
enzyme topoisomerase II, which unwinds DNA for transcription. Doxorubicin 
stabilizes the topoisomerase II complex after it has broken the DNA chain for 
replication, preventing the DNA double helix from being sealed and thereby stopping 
the process of replication (Yoo and Park, 2000).  
 
 
2.4 Vitamin E TPGS 
2.4.1 Chemistry of Vitamin E TPGS 
Vitamin E TPGS or simply TPGS (d-α-tocopheryl polyethylene glycol 1000 
succinate) is a water-soluble derivative of natural vitamin E that prepared by 
esterification of d-α-tocopheryl acid succinate with polyethylene glycol 1000. Its 
molecular weight is 1542 Da and HLB (hydrophile/lipophile balance) is ~ 13. It is 
stable in air. Thermal degradation temperature of TPGS is 199°C and its melt 
temperature is around 38 to 41°C. TPGS has a relatively low critical micelle 













Figure 2-5 Chemical structure of TPGS. 
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 The chemical structure of TPGS is shown in Fig. 2-5. It consists of a tocopherol 
(vitamin E) hydrophobic group and a PEG hydrophilic group, resulting in amphiphilic 
properties. Its bulky structure and large surface area make it an excellent emulsifier. It 
can emulsify a wide range of water-oil immiscible systems. It has been used as 
emulsifier, solubilizer, bioavailability enhancer of vitamin E and some hydrophobic 
drugs and colloidal drug delivery vehicles. National cancer institute (NCI) indicates 
that the safety oral dosage of TPGS is larger than 1 g/kg/day as detected 
(http://www.eastman.com). In 2005, TPGS was approved as a pharmaceutical 
excipient for oral drug formulations in Japan by the Ministry of Health, Labour and 
Welfare in Japan (http://www.in-pharmatechnologist.com). 
 
2.4.2 Application in drug delivery 
2.4.2.1 Bioavailability enhancer 
Co-administration of vitamin E TPGS has been found to increase the oral 
bioavailability of cyclosporine A in healthy dogs by non-compartmental 
pharmacokinetic analysis (Fischer et al., 2002). Cyclosporine is an 
immunosuppressive agent used for preventing the graft rejection in organ transplants. 
Besides, vitamin E TPGS can act as a reversal agent of P-glycoprotein mediated multi 
drug resistance and inhibit P-glycoprotein substrate drugs transport and thus enhance 
absorption of a drug through the intestinal wall and into the bloodstream (Dintaman 
and Silverman, 1999; Rege et al., 2002). P-glycoprotein (the family of multidrug 
resistance-associated proteins) is primarily expressed on the luminal surface of 
epithelial cells from several tissues such as intestine, liver, kidney, and the endothelial 
cells. Vitamin E TPGS can also increase the solubility and Caco-2 cell permeability of 
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 amprenavir and paclitaxel by inhibiting the efflux system and thus enhance their oral 
bioavailability (Ryu et al., 2000). 
 
2.4.2.2 Anticancer property 
Vitamin E TPGS in fact is a derivative of α-tocopheryl succinate (TOS). TOS is a 
succinyl derivative of Vitamin E and has been found with anticancer properties 
against leukemias, melanomas, breast, colorectal, malignant brain, lung and prostate 
cancers (Malafa and Neitzel, 2000; Barnett et al., 2002). TOS were found to inhibit 
the tumors growth in animals by alone or in combination with other anticancer agents 
whereas being non-toxic to normal cells such as naematopoeitic cells, fibroblasts, 
endothelial cells, cardiomyocytes, hepatocytes and smooth muscle cells (Neuzil et al., 
2001; Barnett et al., 2002; Neuzil, 2003). Recently, the anticancer property of TPGS 
was studied by Youk et al. (2005). The study found that TPGS inhibited the growth of 
human lung carcinoma cells implanted in nude mice, and in an in vitro cell culture, 
even more potently than TOS. The superior anticancer efficacy of TPGS is associated 
with its increasing ability to induce apoptosis. 
 
2.4.2.3 Excellent emulsifier/additive 
TPGS can be a good emulsifier or surfactant in fabricating 
nanoparticles/microparticles for the controlled drug delivery system. TPGS emulsified 
PLGA nanoparticles fabricated by a modified solvent extraction/evaporation method 
are not only spherical in shape but also have narrow polydispersity range. TPGS can 
greatly improve the drug encapsulation efficiency (up to 100% EE achieved), enhance 
cellular uptake of nanoparticles and hence increase the therapeutic effects, in addition 
to high emulsification efficiency (67-times higher than PVA) (Mu and Feng, 2002; 
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 2003; Feng et al., 2004; Khin and Feng, 2005). Ke et al. (2005) also demonstrated that 
TPGS can be as a surfactant used in oral delivery of protein drugs and in synthesis of 
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 CHAPTER 3 MATERIALS AND METHODS 
 
3.1 Chemical reagents 
Polymers/Monomers: 
• Poly(D,L-lactide-co-glycolic acid) (PLGA, L:G molar ratio: 50:50, MW 
40,000-75,000) was from Sigma (St. Louis, MO, USA); 
• Poly(vinyl alcohol) (PVA, Mw 30,000-70,000) was from Sigma(St. Louis, MO, 
USA); 
• D,L-lactide and glycolide was from Purac (Gorinchem, Netherland); 
• Glycolide was from Purac (Gorinchem, Netherland) 
 
Organic solvents: 
• Dichloromethane (DCM) was from Fisher Scientific (NJ, USA); 
• Tetrahydrofuran (THF, HPLC grade) was from Fisher Scientific (NJ, USA); 
• N, N-dimethylformamide (DMF) was from Tedia (USA); 
• Dimethyl sulfoxide (DMSO, anhydrous) was from Tedia (USA); 
• Ethyl acetate was from Merck (Germany); 
• Acetone was from Merck (Germany). 
 
Others: 
• Bovine serum albumin (BSA) was from Sigma (St. Louis, MO, USA); 
• Fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA) was 
from Sigma (St. Louis, MO, USA); 
• Doxorubicin hydrochloride was from Sigma (St. Louis, MO, USA); 
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 • Stannous octoate was from Sigma (St. Louis, MO, USA); 
• P-nitrophenyl chloroformate (NPC) was from Sigma (St. Louis, MO, USA); 
• 3-(4,5-cimethylthiazol-z-yl)-2,5-diphenyl tetrazolium bromide (MTT) was 
from Sigma (St. Louis, MO, USA); 
• N,N’-dicyclohexylcarbodiimide (DCC) was from Sigma (St. Louis, MO, 
USA); 
• N-hydroxysuccinimide (NHS) was from Sigma (St. Louis, MO, USA); 
• 4-dimethylamino pyridine (DMAP) was from Sigma (St. Louis, MO, USA); 
• Glutaric acid was from Sigma (St. Louis, MO, USA); 
• Folic acid was from Sigma (St. Louis, MO, USA); 
• Ethylene diamine was from Sigma (St. Louis, MO, USA); 
• Triethylamine (TEA) was from Sigma (St. Louis, MO, USA); 
• Phosphate buffered saline (PBS) was from Sigma (St. Louis, MO, USA); 
• Sodium azide was from Merck (Germany); 
• Pyridine was from Merck (Germany); 
• Vitamin E TPGS was from Eastman (TN, USA); 
• Protein assay kit (Cat. No. 500-0002) was from Bio-Rad (Hercules, CA, 
USA); 
• Propidium iodide (PI) was from Molecular Probes (Singapore); 
• Fetal bovine serum (FBS) was from Hyclone Company (UT, USA);  
• Trypsin-EDTA was from Gibco (Life Technologies, AG, Switzerland); 
• RPMI medium without folic acid was from Gibco (Life Technologies, AG, 
Switzerland); 
• Penicillin-streptomycin solution was from Gibco (Life Technologies, AG, 
Switzerland); 
  30 
 • Milli-Q water was produced by a Milipore water purification system (Milipore 
Corporation, Bedford, OH, USA). 
 
All the above chemicals were of the commercially highest grade and used as received 





3.2.1 Synthesis of copolymer and conjugates 
3.2.1.1 Synthesis of PLA-TPGS copolymer 
PLA-TPGS copolymers of various PLA:TPGS composition ratios were synthesized 
by the ring-opening bulk polymerization of lactide monomer with TPGS in the 
presence of stannous octoate as a catalyst (Fig. 3-1) (Zhang et al., 2006a). In brief, 
weighed portions of lactide and TPGS were added in an ampoule together with 
0.5 wt% stannous octoate (in distilled toluene). The ampoule was then immersed in 
liquid nitrogen and evacuated for 45 mins to remove moisture and oxygen from the 
reagents. The ampoule was then sealed with a butane burner and allowed to react at 
145 ºC in silicone oil bath for 12 h. At the end of polymerization, the product was 
cooled to ambient temperature and then dissolved in DCM. The solution was added to 
excess cold methanol and then precipitated overnight to remove unreacted lactide 
monomer and TPGS. The final product was collected by filtration and vacuum dried at 
45 ºC for two days. 
 


























































Fig. 3-1 Synthetic scheme of PLA-TPGS copolymer. 
 
3.2.1.2 Synthesis of DOX-PLGA-TPGS conjugate 
 
The synthetic scheme is shown as Fig. 3-2. PLGA-TPGS copolymer was synthesized 
by ring-opening polymerization mechanism with the presence of lactide, glycolide and 
TPGS (Zhang et al., 2006a). In brief, lactide, glycolide, TPGS and 0.5% stannous 
octoate were reacted at 145 ºC for 12 h in a sealed glass ampoule under vacuum. The 
product was dissolved in DCM and then precipitated in cold methanol. The copolymer 
was recovered in a vacuum-oven for 2 days at 45 ºC.  
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Fig. 3-2 Synthetic scheme of DOX-PLGA-TPGS. 
 
The synthesized PLGA-TPGS copolymer was activated by adding NPC and pyridine 
(PLGA-TPGS/NPC/pyridine = 1/2/4 in stoichiometric molar ratio) at 0 ºC (Yoo and 
Park, 2001). After recovering the activated PLGA-TPGS from cold diethyl ether, it 
was reacted with DOX in DMF with the presence of TEA for 24 h at room 
temperature. The product was then precipitated in cold methanol and collected under 
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 vacuum drying. The reddish product obtained was further purified by dialyzing 
extensively against Millipore water for 36 h (Spectra/Por, MWCO 1000) to remove 
the unconjugated DOX. All the reactions above were carried out under nitrogen 
atmosphere. The DOX content conjugated with copolymer was determined by 
microplate reader (GENios, Tecan) with excitation wavelength at 480 nm and 
emission wavelength at 580 nm in DMSO. 
 
3.2.1.3 Synthesis of TPGS-FOL conjugate 
 
Synthesis of TPGS-FOL involved preparation of TPGS-NHS and FOL-NH2 as shown 
schematically in Fig. 3-3. TPGS-NHS was prepared by reacting TPGS, glutaric acid 
and DCC (TPGS/glutaric acid/DCC = 1/1/1 in stoichiometric molar ratio) in DMSO 
under nitrogen atmosphere at room temperature for 24 h. The product was filtered to 
remove N,N-dicyclohexylurea (DCU) and then dialyzed against DMSO for 24 h to 
remove excess DCC and against water for 24 h to remove DMSO. After that, the 
resulting product was freeze-dried and then reacted with NHS in the presence of DCC 
at 50 ºC for 6 h (carbonated TPGS/NHS/DCC=1/2/2 in stoichiometric molar ratio). 
The amination of folic acid was prepared as reported by Lee et al (Lee et al., 2003). 
Folic acid (2 mmol) dissolved in 60 ml DMSO was reacted with DCC (2.4 mmol) and 
NHS (4 mmol) at 50 ºC for 6 h. The resulting activated folate was mixed with 
ethylene diamine (40 mmol) in the presence of pyridine as catalyst. The aminated 
folate, FOL-NH2, was precipitated out by adding excess acetonitrile followed by 
vacuum filtration. Finally, TPGS-NHS and FOL-NH2 were allowed to react in DMSO 
at room temperature under nitrogen atmosphere for two days at a molar ratio of 1:2. 
The resulting mixture was dialyzed against DMSO and then water for 24 h. The final 
yellowish product was then collected by freeze-drying.  
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Fig. 3-3 Synthetic scheme of TPGS-FOL. 
 
3.2.2 Characterization of copolymer and conjugate 
3.2.2.1 FT-IR and 1H NMR 
The molecular structure of copolymers and conjugates were investigated by FT-IR 
(Shimadzu, Japan). The samples for FTIR analysis were prepared by grinding 99% 
KBr with 1% copolymer and then pressing the mixture into a transparent pellet. The 
TPGS content and number-averaged molecular weight (Mn) of the copolymers was 
determined by 1H NMR in CDCl3 at 300MHz (Bruker ACF300).  
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 3.2.2.2 GPC 
The Mn and molecular weight distribution of the copolymers was determined by gel 
permeation chromatography (GPC, Agilent 1100 series GPC analysis system with RI-
G1362A refractive index detector).  Agilent PLgel 5 µm mixed-C 300×7.5mm column 
was used. The mobile phase was THF delivered at a flow rate of 1 ml/min. The 
injection volume was 50 µl sample solution (0.5% w/v copolymer in mobile phase). 
Polystyrene standard samples of molecular weights 6.95×105, 5.04×104, 2.26×103 and 
162 were used to generate the calibration curve and the Mn of the samples were 
estimated by the equipment software. 
 
 
3.2.3 Preparation of Nanoparticles 
3.2.3.1 Preparation of BSA-loaded nanoparticles  
BSA-loaded PLA-TPGS nanoparticles were fabricated by double emulsion method. In 
brief, an aqueous solution of BSA (5% w/v) was emulsified into an organic phase 
consisting of 5 ml of copolymer solution in DCM (15 mg/ml) to form primary water-
in-oil (w/o) emulsion using a probe sonicator (55W for 30s) over an ice bath. The w/o 
emulsion was further emulsified into an aqueous solution of PVA (0.5% w/v) by 
sonication for 2 min to form a multiple water-in-oil-in-water (w/o/w) emulsion. The 
emulsion was stirred overnight to evaporate the DCM and then recovered by 
centrifugation at 11,500 rpm for 20 min at 4 oC. The resulted pellet was washed thrice 
to remove PVA and unloaded BSA, then resuspended in water before lyophilization to 
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 3.2.3.2 Preparation of DOX-loaded nanoparticles 
The DOX-loaded nanoparticles of the TPGS-FOL and DOX-PLGA-TPGS blends 
were prepared by a modified solvent extraction/evaporation method. We use 0%, 
20%, 33%, 50% TPGS-FOL nanoparticles to denote the nanoparticles of 0%, 20%, 
33%, 50% TPGS-FOL in the blends of the two conjugates. The weight ratios between 
DOX-PLGA-TPGS and TPGS-FOL in these blends are thus 1:0, 4:1, 2:1, 1:1, 
respectively. The blends of the DOX-PLGA-TPGS and TPGS-FOL blends at various 
weight ratios were dissolved in DCM at a blend concentration of 12.5 mg/ml. DOX 
was dissolved in acetone in the presence of TEA (molar ratio of DOX:TEA=1:2), then 
mixed with the blend solution and vortexed for 60 s. The formed solution was poured 
into aqueous phase under gentle stirring and then sonicated for 120 s at 25 W output. 
The emulsion was evaporated overnight and then centrifuged at 10, 500 rpm for 20 
min. The pellet was resuspended in water and freeze-dried for 2 days to get the 
nanoparticles powder. One feature of such a formulation is that no emulsifier is 
needed in preparation of the drug loaded nanoparticles since the two conjugates 
already contain TPGS, which resulted in self-emulsification effect. 
 
3.2.4 Characterization of nanoparticles 
3.2.4.1 Particle size and size distribution 
The size and size distribution of BSA-loaded nanoparticles were measured by LLS (90 
Plus Particle Sizer, Brookhaven Instruments, USA). The dried nanoparticles were 
redispersed in deionized water using a bath sonicator before measurements. The value 
was recorded as the mean of seven measurements. The size distribution is given by 
polydispersity index (PI, a value between 0 to 1). A PI of 1 indicates large variations 
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 in particle size; a PI of 0 indicates no variation in particle size (an ideal monodisperse 
formulation) (Schiffelers et al., 2001).  
 
3.2.4.2 Surface charge 
Zeta potential of the nanoparticles was measured by the laser Doppler anemometry 
(zeta Plus, Zeta Potential Analyzer, Brookhaven Instruments Corporation). Samples 
from the prepared suspensions were diluted in deionized water and placed in the 
measurement cell. A measurement of 7 runs was taken for each sample. 
 
3.2.4.3 Surface morphology 
The morphology of the nanoparticles was observed with a field emission scanning 
electron microscopy (FESEM, JEOL, SM-6700F, Japan). Samples were mounted on 
aluminium stubs using a double-sided conductive tape and then sputter-coated with 
platinum using an automatic fine platinum coater (JEOL, JFC-1300, Japan) for 60 s.  
 
3.2.4.4 Surface chemistry 
An XPS (AXIS His-165 Ultra, Kratos Analytical, Shimadzu) was used for analyzing 
the surface chemistry of nanoparticles. A full spectrum scan was performed over a 
binding energy of 0-1200 eV at a passing energy of 80 eV. Detailed analysis for C 1s, 
O 1s, N 1s of the samples were conducted over 279-292 eV, 525-537 eV and 392-404 
eV, respectively with a pass energy of 40 eV. Curve fitting was performed by a 
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 3.2.5 Drug encapsulation efficiency 
3.2.5.1 Encapsulation efficiency of BSA in nanoparticles 
Actual loading of BSA in nanoparticles was determined by an extraction method 
(Ruan et al., 2002). The BSA-loaded PLA-TPGS nanoparticles were dissolved in 
DCM and then extracted by Milli-Q water. The mixture was centrifuged at 3,000 rpm 
for 5 min and the supernatant was collected for protein assay by the Bradford’s 
method (Bradford, 1976). The absorbance at 485 nm was measured using a microplate 
reader (GENios, Tecan, Switzerland) in comparison with a standard curve obtained by 
assaying known concentrations of a BSA standard solution. The process of extraction 
was repeated thrice. Each sample was assayed in triplicate for two different batches.  
 
3.2.5.2 Encapsulation efficiency of DOX in nanoparticles 
The drug EE was determined by measuring the DMSO solution contained freeze-dried 
nanoparticles at excitation wavelength of 480 nm and emission wavelength of 580 nm. 
A calibration curve was constructed using different concentrations of free DOX in 
DMSO. The drug EE was then calculated based on the weight ratio of the drug 
amount formulated in the nanoparticles to that added in the fabrication process. Each 
sample was assayed in triplicate for two different batches.  
 
3.2.6 In vitro release  
3.2.6.1 In vitro BSA release and degradation of nanoparticles 
BSA-loaded nanoparticles (5 mg) were incubated with 1 ml release medium (PBS 
buffer, 0.02% sodium azide, pH 7.4) in an Eppendorf tube in a water bath rotary 
shaker at 110 rpm at 37 oC. At predetermined intervals, the nanoparticles suspension 
was centrifuged at a speed of 11,500 rpm for 20 min. The supernatant of each sample 
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 was analyzed for the amount of released BSA using the Bradford’s method and 
replaced with 1 ml fresh release medium. For nanoparticles degradation studies, the 
similar procedure was performed. The pH variations of the release medium taken out 
from the nanoparticles suspension at various predetermined intervals were measured 
by a pH meter (ORION 525A, USA). The nanoparticles pellets at various time points 
were freeze-dried and their molecular weight was determined by GPC using THF as 
mobile phase at a flow rate of 1 ml/min. The surface morphology of the pellets 
(degraded nanoparticles) was analyzed by FESEM (JEOL, SM-6700F, Japan).  
 
3.2.6.2 In vitro DOX release 
In vitro drug release from the nanoparticles was performed in triplicate, in PBS (0.1 
M, pH 7.4) at 37 ºC. Nanoparticles were dispersed in PBS in a centrifuge tube and 
then put in an orbital water bath operating at 120 rpm at 37 ºC. At predetermined time 
intervals, the samples were centrifuged at a speed of 10, 500 rpm for 20 min. The 
supernatant was transferred to a 24-well transparent plate and detected by a microplate 
reader (GENios, Tecan) with excitation wavelength at 480 nm and emission 
wavelength at 580 nm. The release amount of DOX was calculated by the calibration 
curve of DOX in PBS, ranging from 0-1 µg/ml with R2=0.9955. The pellet was 
resuspended in fresh PBS medium, then put back into the water bath shaker for 
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 3.2.7 Stability of released BSA 
3.2.7.1 SDS-PAGE 
The primary structural integrity of released BSA was detected by SDS-PAGE in 
comparison with native BSA and reference markers. All the gels were run under non-
reducing conditions using Mini-Protean II electrophoresis unit from BioRad at a 
constant voltage mode of 200V in a Tris/glycine/SDS buffer. The gels were stained 
with silver to reveal protein, destained and dried. 
 
3.2.7.2 Circular dichroism (CD) spectroscopy 
The changes in the secondary structure of the released BSA with respect to the native 
BSA were measured by CD spectroscopy (Jacob J810 spectropolarimeter) with a 5 
mm quartz cylindrical cell. Solutions of native BSA and released BSA were scanned 
over the wavelength range of 200-260 nm. A three protein spectra were collected and 
averaged. 
 
3.2.8 Cell line experiment 
3.2.8.1 Cell culture 
Human colon adenocarcinoma (Caco-2) cells and NIH-3T3 fibroblast cells (American 
Type Culture Collection, VA, USA) were cultured in Dubelco’s modified essential 
medium (DMEM) supplemented with 10% FBS, 100 mM sodium pyruvate, 1.5 g/l of 
sodium bicarbonate and 1% penicillin-streptomycin. Human breast adenocarcinoma 
(MCF-7) cells and C6 glioma cells (American Type Culture Collection, VA, USA) 
were cultured in RMPI 1640 medium without folic acid supplemented with 10% FBS 
and 1% penicillin-streptomycin. All the cells were incubated in SANYO CO2 
incubator at 37 oC in a humidified environment of 5% CO2. The medium was 
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 replenished every other day until confluency was reached. The cells were then washed 
twice with PBS and harvested with 0.125% of Trypsin-EDTA solution. 
 
3.2.8.2 In vitro cytotoxicity studies 
MCF-7 and C6 cells harvested in a logarithmic growth phase were seeded in a 96-well 
transparent plate (Costar, IL, USA) for 24 h. The medium was then changed with 
different concentrations of free DOX or DOX-loaded nanoparticles (0.002 µM to 100 
µM in culture medium). MTT assay was performed and the percentage of cell viability 
was determined at 570 nm. At designed time intervals, the medium was removed and 
the wells were washed two times with PBS. The cells were incubated with 90 µl 
medium and 10 µl MTT dye (5 mg/ml in PBS) for 3-4 h and the precipitate was 
dissolved in 100 µl isopropanol before analyzed by the microplate reader. Cell 
viability was calculated by the following equation,  




                                                  
)
where Abss is the fluorescence absorbance of the cells incubated with the nanoparticl
suspension and Abscontrol is the fluorescence absorbance of the cells incubated with th
culture medium only (positive control). IC50, the drug concentration at whic
inhibition of 50% cell growth was observed in comparison with that of the contro
sample, was calculated by the curve fitting of the cell viability data. 
 
3.2.8.3 In vitro cellular uptake studies 
Quantitative studies.    MCF-7 and C6 cells were seeded in a 96-well black plat
(Costar, IL, USA). After the cells reached 70-80% confluency, the cells wer
incubated with DOX or DOX-loaded 0% and 50% TPGS-FOL nanoparticles (4.
µg/ml DOX in folate free medium) at 37 ºC for 0.5, 1.5, 4, 6 h, respectively. For eac









 sample, we seeded 6 wells for positive control and 6 wells for sample wells. At the 
assigned interval, the sample wells were washed with 50 µl cold PBS three times and 
then added with 100 µl culture medium. After that, all the wells were lysed by 50 µl 
0.5% triton in 0.2 N NaOH. The fluorescence intensity of each sample well was 
measured by the microplate reader (GENios, Tecan, Switzerland, λex=480 nm and λem 
=580 nm) calibrated with standard solutions of DOX (0.1 to 20 µg/ml). Cellular 
uptake efficiency was expressed as: 
Uptake efficiency (%) =
Is
Icontrol        
)
Where Is is the fluorescence intensity associated with cell while Icontrol is th
fluorescence intensity associated with the total amount of nanoparticles (positiv
control). 
 
Qualitative studies. The cells were harvested and reseeded in a chamber cover glas
system (LAB-TEK, Nalge Nunc, IL), maintained with 5% CO2 at 37oC until 70-80%
of confluency was reached. The cell monolayers were incubated with 500 µL of 25
µg/mL of FITC-BSA loaded nanoparticles or DOX-loaded nanoparticles suspensio
for 2 h at 37oC. After that, the cells were washed thrice with cold PBS and then fixe
by 75% ethanol for 20 min. The cells were then further rinsed twice, followed b
counterstaining the nucleus with 30 µl of propidium iodide (PI, 20 µg/ml in PBS
After washing the cells for two times with PBS, the cell monolayer was observed b
the confocal laser scanning microscope (CLSM, Zeiss LSM 410, Germany) wit
imaging software (Fluoview FV300). Note that the process of counterstaining the ce
nucleus with PI was omitted for DOX-loaded nanoparticles. 
 













 CHAPTER 4  NANOPARTICLES OF POLY(LACTIDE) 
– TOCOPHERYL POLYETHYLENE GLYCOL (PLA-




There has been intensive research interest on controlled delivery of proteins and 
peptides over the past years since various therapeutic proteins such as vaccines, 
hormones, growth factors and enzymes were developed from biotechnology (Langer 
and Folkman, 1976; Talmadge, 1993). Peptides and proteins have problems in their 
delivery, including easy hydrolysis, poor biological membranes penetration and short 
physiological half-lives in the gastric and intestinal fluid (Couvreur and Puisieux, 
1993). Oral bioavailability is low and clinical applications are restricted. In order to 
overcome these problems, microparticles/nanoparticles of biodegradable polymers 
have emerged as a potential solution for controlled delivery as well as for oral delivery 
of protein and peptide drugs. Compared with microparticles, nanoparticles can be 
adsorbed through the gastrointestinal (GI) barrier and taken by Peyer’s patches, 
thereby enhancing the oral bioavailability of the encapsulated molecular drugs 
(Florence, 1997; Jani et al., 1989; 1992). In this research, therefore, we focused on 
protein-loaded nanoparticles instead of protein-loaded microparticles. 
 
The polymeric matrix of nanoparticles plays an important role in protein loading, 
stability and bioavailability. Various FDA-approved biodegradable polymers are 
commercially available for drug delivery by nanoparticle formulation. Those used 
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 most often in this area include PLA, PLGA and PCL, most of which could not achieve 
desired effects in nanoparticle formulation since they were originally synthesized not 
for drug delivery purpose (mainly for textile grafts and implants) in the 1950’s (Feng, 
2006). They are highly hydrophobic and thus not friendly to hydrophilic drugs such as 
peptides, proteins and antigens. The bioactivity of the encapsulated proteins and 
peptides may also be deteriorated since their hydrophobic nature prevents penetration 
of water into the core of the nanoparticles, resulting in an acidic micro-environment 
due to the accumulated acidic breakdown byproducts such as lactic and glycolic acid 
end groups (Fu et al., 2000; Zhou, 2003). Their hydrophobic nature may also cause 
adsorption of protein molecules to the polymer surface which can catalyze protein 
aggregation and further impair the intended release profile, leading to burst release or 
incomplete release of encapsulated proteins and peptides (Uchida et al., 1995; Cao and 
Shoichet, 1999). For manipulating the hydrophobicity of polymers such as PLA, new 
blocks of desired properties should be introduced into PLA to form novel 
biodegradable block copolymers of desired mechanical and physical properties. We 
were thus inspired to synthesize PLA-TPGS copolymer for nanoparticle formulation 
of small molecule anticancer drugs as well as protein and peptide drugs for 
chemotherapy. Encouraging results have been obtained for small molecule anticancer 
drugs such as paclitaxel. It was found that paclitaxel-loaded PLA-TPGS nanoparticles 
can have much higher drug EE and achieve much faster drug release than the 
paclitaxel-loaded PLGA nanoparticles to meet the therapeutic needs. In vitro Caco-2 
cell line experiment also demonstrated that PLA-TPGS nanoparticles possess great 
potential for oral delivery of anticancer drugs (Zhang and Feng, 2006b; 2006c). 
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 In this chapter, we develop PLA-TPGS nanoparticles for controlled oral delivery of 
peptide/protein drugs with BSA as a model protein. BSA-loaded PLA-TPGS 
nanoparticles were prepared by the double emulsion technique. Influence of the TPGS 
content of the copolymers and the BSA loading level on the protein EE and in vitro 
release behavior was investigated. The degradation and intracellular uptake of the 
PLA-TPGS nanoparticles in vitro were also studied. 
 
 
4.2 Result and discussion  























Figure 4-1 Chemical structure of PLA-TPGS copolymer. 
 
 
The chemical structure of the PLA-TPGS copolymers prepared in this study was 
shown in Fig. 4-1. The synthesized PLA-TPGS copolymers were characterized by 1H 
NMR (Fig. 4-2). The signals at 5.2 and 1.69 ppm were assigned to methine protons (-
CH) and methyl protons (-CH3) of PLA segment, respectively while the peak at 3.65 
ppm was assigned to the methylene (-CH2) protons of PEO part of TPGS. CH protons 
peak of lactide monomer which was at 5.07 ppm had shifted to 5.2 ppm in the 
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 spectrum of PLA-TPGS copolymer, indicating the formation of PLA-TPGS 
copolymer. Unreacted lactide monomers were successfully removed by the 
precipitation process as the CH proton peak that due to lactide monomer (at 5.07 ppm) 
was not observed in the spectrum of PLA-TPGS copolymer. 
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Fig. 4.2 1H NMR spectra of monomers and PLA-TPGS copolymer in CDCl3. 
 
The Mn of PLA-TPGS copolymers can be calculated by using the peak areas at 5.2 
ppm (or 1.69 ppm) and 3.65 ppm with the following formulae: 
4 × 23 ÷ P3.65 = 
PLAM
72
 ÷ P5.2                                                                                       (4.1)
(4.2)Mn = MPLA + MTPGS                                                                                                      
where Mn represents the number-averaged molecular weight of the copolymers, MPLA 
is the molecular weight of the PLA part of the copolymers, MTPGS is the molecular 
weight of TPGS (1542 g/mol), P3.65 and P5.2 represent the integrated peak area at 3.65 
ppm and 5.2 ppm, respectively. The characterization results by 1H NMR and GPC 
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 were tabulated in Table 1. The synthesized PLA-TPGS copolymers were found with 
polydispersity, being around 1.6 and TPGS contents ranging from 3.4% to 12.0%.  
 
Table 4-1. Characteristics of PLA-TPGS copolymers 
Molecular weight b 
Copolymer name TPGS feed content (%) 
TPGS  
content a 
(%) Mw  Mn PI (Mw/Mn) 
PLA-TPGS 97:3 7.0 3.4 31,600 18,700 1.69 
PLA-TPGS 94:6 10.3 6.0 25,300 16,300 1.56 
PLA-TPGS 88:12 15.0 12.0 15,500 10,600 1.46 
 
a Calculated by 1H NMR 
b Calculated by GPC 
 
 
4.2.2 Effects of formulation variables on nanoparticle characteristics 
4.2.2.1 Effects of BSA loading 
Table 4-2 shows the effects of BSA loading on the properties of nanoparticles. An 
increase in BSA loading ranging from 6.3% to 28.6% reduced the BSA EE in the 
PLA-TPGS nanoparticles from 80.1% to 53.1%. This observation is understandable 
because the higher BSA loading would cause higher BSA concentration gradient 
between the emulsion droplets and the outer aqueous phase and as a result, leading to 
a higher BSA loss in the fabrication process. Similar observation had been reported by 
other researchers (McGee et al., 1994; Ohagan et al., 1994).  Each type of polymeric 
nanoparticles may have its own threshold of drug encapsulation. Once the threshold 
was reached, the increase in the drug loading would actually cause more drugs to be 
wasted away during the fabrication process and detrimental to the drug EE in the 
nanoparticles. For our PLA-TPGS nanoparticles, it was noticed that when the BSA 
loading was 28.6%, the EE could still be as high as 53.1%.  Perhaps, this implied that 
PLA-TPGS copolymer could have a high threshold for BSA encapsulation.  
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 Table 4-2. Effects of protein loading on characteristics of BSA-loaded  












Yieldc (%) PI EE
d (%) 
6.3 5.0 329±19 75.7±4.4 0.19±0.02 80.1±4.2 
11.8 8.4 341±15 71.5±4.6 0.25±0.02 71.4±3.1 
16.7 11.5 323±16 71.3±3.2 0.29±0.03 68.8±2.7 
21.1 12.3 338±13 67.5±5.1 0.28±0.02 58.3±3.5 
28.6 15.2 325±18 65.3±4.8 0.30±0.01 53.1±3.8 
 
Copolymer used: PLA-TPGS 94:6 
aTheoretical BSA loading(%) = [weight of BSA used/ (weight of polymer + BSA used)] x 100 
bActual BSA loading(%) = [weight of actual BSA loaded in NP/ weight of Nanoparticles obtained]x 100 
cNanoparticles Yield (%) = [weight of recovered Nanoparticles/ (weight of polymer + BSA used]) x 100 




4.2.2.2 Effects of TPGS content 
 
A BSA loading of 16.7% was chosen as the condition for studying the effects of 
different TPGS contents in the copolymers on fabrication of the BSA-loaded PLA-
TPGS nanoparticles. The results are shown in Table 4-3. It was obvious that the 
particle size was reduced significantly from 362 nm to 274 nm when the content of 
TPGS in the copolymers was increased from 3.4% to 12.0%. However, the BSA EE 
also decreased drastically from 75.6% to only 44.3%. It is known that the polymer 
solution of high viscosity should be more difficult to be broken down into smaller 
droplets, hence causing formation of larger particles (Yang et al., 2001b). It was 
postulated that at a constant volume, the higher the TPGS content, the lower the 
molecular weight of the copolymer, and the lower viscosity of the polymer solution, 
and therefore, resulting in the smaller nanoparticles formation. The decrease in the 
BSA EE could most likely be due to the decrease in particle size and the increase of 
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 the hydrophilicity of the copolymers with higher TPGS content. The enhanced 
hydrophilicity of the copolymers would facilitate BSA diffusion through the 
copolymer matrix into the water phase during the solvent evaporation of the 
nanoparticles, which could cause BSA loss and resulted in lower EE.  
 
Table 4-3. Effects of TPGS content of PLA-TPGS copolymers on characteristics of 









PLA-TPGS 97:3 362±18 0.34±0.02 12.6 75.6±3.8 
PLA-TPGS 94:6 323±16 0.29±0.03 11.5 68.8±2.7 
PLA-TPGS 88:12 274±20 0.21±0.03 7.4 44.3±3.6 
PLGA 330±15 0.22±0.05 10.8 64.5±2.2 
 
Theoretical BSA loading: 16.7% 
aActual BSA loading(%) = [weight of actual BSA loaded in NP/weight of Nanoparticles obtained] x 100 
bEE(%) = [Theoretical BSA loading/ Actual BSA loading] x 100 
 
 
Furthermore, Ruan et al. (2002) reported that the involvement of either low (2%) or 
high (10%) concentrations of TPGS as additive in fabricating HSA-loaded PLGA and 
PELA nanoparticles had decreased the EE by around 25% compared to that of no 
additive being added. However, our results showed that involvement of low (3.4%) 
and moderate (6.0%) content of TPGS in the copolymers had enhanced EE of the 
PLA-TPGS nanoparticles compared with that of the PLGA nanoparticles. This 
demonstrated the advantages of grafting TPGS into the polymer rather than using 
TPGS as an additive in fabricating BSA-loaded nanoparticles. The grafted TPGS 
could eliminate the problem of displacement of the drug molecules from the w/o 
emulsion interface by the additives/surfactants (De Rosa et al., 2000; Ruan et al., 
2002). This was important because the displacement of BSA by the 
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 additives/surfactant would be detrimental to the BSA EE. It should be mentioned that 
there was no significant difference on the nanoparticle yield among each formulation 
(around 68%-71%). 
 
4.2.3 Surface chemistry of BSA-loaded PLA-TPGS nanoparticles 
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Fig. 4-3 XPS spectra (wide scan) of BSA-loaded PLA-TPGS 94:6 nanoparticles. The 
inset shows the nitrogen signal at high resolution. 
 
 
Surface chemistry of the BSA-loaded PLA-TPGS nanoparticles was analyzed by XPS. 
XPS is a sensitive surface analysis method that can detect 0.1% of an element existing 
on a surface. It has been widely used to analyze the atomic composition of the 
nanoparticles/microparticles surface (Quellec et al., 1998; Yang et al., 2001b; Zhang 
and Feng, 2006a). A nitrogen signal can be used to determine if the BSA is absorbed 
on the surface of nanoparticles or distributed inside the nanoparticles because nitrogen 
atoms are only element present in BSA, but not in PVA and PLA-TPGS copolymer. 
The XPS spectra of BSA-loaded PLA-TPGS nanoparticles were shown in Fig. 4-3, 
demonstrated that no nitrogen signals were detected on the surface of the copolymers 
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 nanoparticles. This indicated that the BSA was mainly entrapped in the PLA-TPGS 
nanoparticles.  
 
Fig. 4-4 shows the C1s XPS spectra of PLA-TPGS copolymer and BSA-loaded PLA-
TPGS nanoparticles. The peak (C-O-C) at the binding energy of 286 eV was regarded 
as the indicator of the PEG component of the PLA-TPGS copolymer (Peracchia et al., 
1997; Zhang and Feng, 2006a). From Fig. 4-4, we observed that there was an 
increased C-O-C peak ratio from 12.1% for the PLA-TPGS 94:6 copolymer to 15.8% 
for the BSA-loaded PLA-TPGS 94:6 nanoparticles. This let us presume that part of 
the TPGS was present on the nanoparticle surface, which resembled to the case of the 
PEG-coated microspheres that reported by Quellec et al. (1998). This observation is 
reasonable because TPGS is a water-soluble component of PLA-TPGS copolymers, it 
would tend to orient itself to the external water surface and inner aqueous phase 
during nanoparticles formation process. This phenomenon was also observed in 
previously reported for PLA-TPGS, PLA-PEG nanoparticles/microparticles (Quellec 
et al., 1998; Zhang and Feng, 2006a). 
 
 











Fig. 4-4 XPS C1s 
BSA-loaded PLA-T
4.2.4 Degradation













high resolution scans of (a) PLA-TPGS 94:6 copolymer and (b) 




of BSA-loaded PLA-TPGS nanoparticles 
A-loaded PLA-TPGS nanoparticles with various TPGS contents 
GPC and the result is shown in Fig. 4-5. PLA-TPGS nanoparticles 
depend very much on the content of TPGS in the copolymers and 
weight of the copolymers. Rate of degradation became faster for 
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 the nanoparticles fabricated from PLA-TPGS copolymers with lower molecular 
weight or higher TPGS content. This is because the copolymer with higher TPGS 
content would have higher hydrophilicity and hence lead to greater ease for erosion of 
the polymeric matrix. The in vitro degradation experiment also demonstrated that our 
PLA-TPGS copolymers were degradable and after 35 days, 16%, 27.2% and 51.5% 






























Fig. 4-5 Degradation behaviors of BSA-loaded PLGA and PLA-TPGS nanoparticles  
in PBS at 37 oC for a period of 5 weeks. Data represent mean ± SD, n=3. 
 
 
Interestingly, the degradation of the BSA-loaded PLGA nanoparticles was found to be 
faster than that of the BSA-loaded PLA-TPGS nanoparticles, regardless of the content 
of TPGS that involved in the copolymers. However, this observation was 
understandable because degradation of PLGA nanoparticles would produce acidic 
oligomeric byproducts which would self-catalyze the degradation of PLGA (Fu et al., 
2000; Cho et al., 2001). Generation of acidic byproducts in the release medium, 
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 however, would cause a decrease in the pH of release medium. Fig. 4-6 shows the 
profile of the pH of the release medium versus the incubation time. For the PLGA 
nanoparticles, the pH decreases much more rapidly in comparison with that for the 
PLA-TPGS nanoparticles. This implies that the PLGA nanoparticles could result in a 
much more severe acidic environment, in which the activity of the released protein 
may deteriorate. Similar results have also been found for the PLGA microparticles 




















Fig. 4-6 pH change of release medium incubated with BSA-loaded NPs at 37 oC. 
SD was < 3% of the mean in all cases, n=3. 
 
 
Fig. 4-7 is FESEM images showing the surface morphology of the BSA-loaded PLA-
TPGS nanoparticles under incubation in PBS at 37 oC over a period of 5 weeks. PLA-
TPGS nanoparticles displayed spherical surface structure with a fairly uniform size 
distribution before degradation. The spherical nanoparticles shrunk and deteriorated 
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 until they collapsed to become a matrix-like structure as observed in the FESEM 
images of the degraded nanoparticles. The nanoparticles prepared from the PLA-
TPGS copolymers of lower TPGS content were able to maintain their spherical shape 
for a prolonged period of time compared with that of higher TPGS content. This result 
was in good agreement with what we observed from the nanoparticle degradation 
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Fig. 4-7 FESEM images of PLA-TPGS nanoparticles of various TPGS content after 
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 4.2.5 In vitro BSA release 
Fig. 4-8(a) shows the release profile of BSA from various nanoparticles of 16.7% 
BSA loading.  The BSA release from the PLGA nanoparticles was characterized as an 
initial burst followed by a slow and then non-release profile. Although the BSA-
loaded PLGA nanoparticles degraded quite sufficiently for a period of 5 weeks (Fig. 
4-5), a non-release profile was observed. This non-release profile of proteins was 
consistent with the results that reported previously in PLA and PLGA delivery 
systems (Cohen et al., 1991; Kim and Park, 1999; Shi et al., 2003). Such non-release 
of BSA has been attributed to the non-covalent protein aggregation and non-specific 
protein adsorption that occurred within PLA/PLGA particles (Crotts and Park, 1997; 
Kim and Park, 1999) as well as the acidic microclimate resulted from the degradation 
of PLGA (Zhu et al., 2000).  
 
Compared with the PLGA nanoparticles, the PLA-TPGS nanoparticles have biphasic 
BSA release profiles with an initial burst, ranging from 24.0% to 34.5% in the first 
day, which was followed by a sustained release pattern over the 30-day study period. 
The rapid initial release was probably due to the BSA that located near the surface of 
nanoparticles and also water-soluble nature of BSA (Bouillot et al., 1999; Lamprecht 
et al., 1999). The gradual release phase might be attributed to the slow diffusion of the 
entrapped protein in the inner part of nanoparticles into the release medium as well as 
polymer erosion or degradation (Coombes et al., 1998; Bouillot et al., 1999). It was 
observed that the BSA release rate increased when the TPGS content in the copolymer 
increased. This is because not only did the hydrophilic portion of TPGS enhance the 
interaction between the nanoparticles and the release medium, but also promote the 
penetration of the release medium into the nanoparticle matrix to cause swelling as 
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 well. Furthermore, the faster release rate of the BSA-loaded PLA-TPGS 88:12 
nanoparticles could also be explained in terms of their smaller particle size compared 
with that of other PLA-TPGS nanoparticles. The relationship between the size of 
microparticles/nanoparticles and the drug release rate was reported to be inversely 
proportional because of the decreased diffusional path length and the increased 
effective surface area to the volume ratio of the microparticles/nanoparticles (Roy et 


















































































Fig. 4-8 In vitro BSA release profiles in PBS at 37 oC for BSA-loaded (a) PLGA and 
PLA-TPGS nanoparticles of various TPGS content and (b) PLA-TPGS 94:6 
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 Fig. 4-8(b) shows the effect of BSA loading on release profile of PLA-TPGS 
nanoparticles. It was observed that the higher the BSA loading, the higher the initial 
burst and the faster the BSA release rate. This observation could be related to the 
driving force of BSA diffusion. A higher BSA loading gave rise to a larger 
concentration gradient between the nanoparticles and the release medium, which 
would increase the driving force for BSA diffusion, leading to faster BSA release 
(Yang et al., 2001a). Indeed, these results suggest that the release rate of the BSA 
from nanoparticles can be manipulated by taking into account the content of TPGS in 
the copolymer and BSA loading. 
 
4.2.6 Stability of BSA released from nanoparticles 
 Protein drug may become inactive due to irreversible protein denaturation or 
aggregation during the nanoparticles fabrication process as a result of using organic 
solvent such as dichloromethane (DCM), probe sonication, vigorous shaking and 
lyophilization (Marchais et al., 1996). Furthermore, generation of acidic micro-
environment within PLGA matrices upon polymer degradation has been identified as 
one of the important source that is deleterious to the stability of encapsulated protein 
(Zhu et al., 2000). For this purpose, we investigated the stability of primary and 
secondary structure of the BSA released from PLA-TPGS nanoparticles. 
 
The stability of primary structure of the BSA released from PLA-TPGS nanoparticles 
was monitored by SDS-PAGE. Fig. 4-9 displays the SDS-PAGE results of the native 
BSA and the BSA released from the nanoparticles under non-reducing condition. The 
non-reducing condition was selected for this analysis in order to verify the presence of 
any aggregates linked by disulphide bonds (Crotts and Park, 1997; Gao et al., 2005). 
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Fig. 4-9 SDS-PAGE of the released BSA from (a) PLA-TPGS 94:
different time intervals. Lane 1, molecular weight markers; lane 2, n
1 day; lane 4, 1 week; lane 5, 2 weeks; lane 6, 3 weeks; lane 7, 4
weeks and (b) PLGA nanoparticles at different time intervals. L
weight markers; lane 2, native BSA; lane 3, 1 week; lane 4, 2 week
lane 6, 4 weeks; lane 7, 5 weeks; lane 8, 6 weeks. 
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 nanoparticles/microparticles by other researchers (Panyam et al., 2003; Gao et al., 
2005). The different intensity of aggregation observed in both gels (Fig. 4-9(a) and 4-
9(b)) was due to different amounts of samples loaded. Our results thus suggest that the 
PLA-TPGS nanoparticles provide a mild environment for the BSA at least in the 
observation period of 5 weeks.  
 
The secondary structure of the natural and released BSA incubated in PBS at 37 oC 
was analyzed by using far UV CD (200-260 nm). The CD spectra of the BSA released 
from PLA-TPGS nanoparticles incubated in PBS for 35 days from various 
nanoparticle formulations are shown in Fig. 4-10.  There were no significant 
alterations in the CD spectra of the BSA released from the PLA-TPGS nanoparticles 
compared with those of the native BSA. Each spectrum displayed two minima at 208 
and 222 nm, which was consistent with others’ studies (Zhu et al., 2000; Jiang et al., 
2001), indicating that the native secondary structure of the released BSA was 
preserved upon protein encapsulation and in vitro release process. Instead, it was 
noticed that intensity of the two minima demonstrated by released BSA from PLGA 
nanoparticles was relatively smaller than that of native BSA, indicating a decrease in 
the α-helix content of the released BSA from the PLGA nanoparticles (Gao et al., 
2005).  
 































Fig. 4-10 CD spectra of 35 day released BSA from various PLA-TPGS nanoparticles. 
 
 
4.2.7 In Vitro Cellular uptake of PLA-TPGS nanoparticles loaded with FITC-
BSA 
In order to evaluate the feasibility of PLA-TPGS nanoparticles as potential delivery 
vehicle for molecular drugs, cellular uptake of fluorescent BSA-loaded PLA-TPGS 
nanoparticles were studied by employing NIH-3T3 and Caco-2 cancer cell lines. NIH-
3T3 cells were used as a model of fibroblast cells and Caco-2 cells were utilized as an 
in vitro model of the gastrointestinal (GI) drug barrier for oral delivery. Caco-2 
monolayers have often been used in the literature as an in vitro model for evaluating 
the intestinal permeability and metabolism of drugs (Chang et al., 1996). Confocal 
microscopic images of NIH-3T3 cells and Caco-2 cells after 2 h incubation with 
FITC-BSA loaded PLA-TPGS nanoparticles at 37 oC are shown in Fig. 4-11(a) and 
(b), respectively. In both cases, the fluorescence of nanoparticles was found to be 
accumulated around the cell nucleus (red, stained by propidium iodide) and 
  64 






Fig. 4-11 Confocal microscopic images of (a)
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 smaller size and more uniform size distribution, higher EE, and desired release profile 
and more importantly, in protecting the activity of the formulated proteins. The PLA-
TPGS nanoparticles are thus of great potential to be an efficient and safe delivery 
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 CHAPTER 5  FOLATE-DECORATED POLY(LACTIDE-
CO-GLYCOLIDE)-VITAMIN E TPGS NANOPARTICLES 
FOR TARGETED DRUG DELIVERY 
 
5.1. Introduction 
Effective cancer chemotherapy is obstructed mainly by the low selectivity of the 
anticancer drugs towards the cancer cells. Also, not only do the anticancer drugs affect 
the cancer cells, but the normal cells as well, which cause severe side effects. Targeted 
drug delivery systems thus are preferred, which have been studied extensively in the 
past few years (Kim and Park, 1999; Lee et al., 2002; Saul et al., 2003; Kukowska-
Latallo et al., 2005). Drug-loaded nanoparticles of biodegradable polymers have great 
potential to provide an ideal solution for most of major problems encountered in 
chemotherapy. Moreover, those of targeting function have become a focus in this area, 
which can be realized by “decorating” the nanoparticle surface with specific ligands 
that can recognize the cancer cells and mediate the ligand-receptor interaction between 
the decorated nanoparticles and the cancer cells (Moghimi et al., 1991). For instance, 
it has been found that folate-receptor, a glycosylphosphatidylinositol (GPI) anchored 
cell surface receptor for folate, is overexpressed on the membrane of brain, kidney, 
breast, ovary and lung cancer cells, while it is absent from most normal cells instead 
(Sudimack and Lee, 2000; Saul et al., 2003). Folic acid, an oxidized form of folate, 
has thus widely been used as a targeting ligand due to its high binding affinity for the 
folate receptors (Kd ~ 10-10 M) (Leamon and Reddy, 2004). In the literature, folate 
decorated liposomes, micelles and nanoparticles of biodegradable polymers such as 
DSPE-PEG, PCL-MEPG, PLGA-PEG, PLGA have been found to increase the cellular 
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 uptake and cell cytotoxicity of the formulated anticancer drugs (Saul et al., 2003; Yoo 
and Park, 2004a; Park et al., 2005b; Lee, 2006; Shmeeda et al., 2006; Wu et al., 2006).  
 
In this study, two types of novel biodegradable conjugates, Vitamin E TPGS-folate 
(TPGS-FOL) and doxorubicin-poly(lactide-co-glycolide)-vitamin E TPGS (DOX-
PLGA-TPGS) were synthesized. TPGS-FOL decorated PLGA-TPGS nanoparticles 
were prepared for targeted drug delivery with doxorubicin (DOX) as a prototype 
anticancer drug. The nanoparticles can also be applied to increase the half-life of the 
drug in the body as well as to achieve oral drug delivery. DOX is an anthracycline 
antibiotic, which is particularly effective for treating breast cancer as well as cancers 
in the ovarian, prostate, brain, cervix and the lung (Blum and Carter, 1974). However, 
DOX was found to have short half-life in the body after injection and large volume of 
distribution because it is the substrate of P-glycoprotein efflux pump, which caused 
lower tumor accumulation and significant toxicity to normal tissues (Minko et al., 
1998). Therefore, the prototype drug was loaded in PLGA-TPGS nanoparticles by 
both physical entrapment and chemical conjugation in our formulation, as alternative 
forms of administering DOX for treatment of cancer. DOX was also terminally 
conjugated to the PLGA-TPGS copolymer to improve its stability in the nanoparticles. 
This idea has been proved feasible by Yoo & Park with their doxorubicin-PEG-folate 
conjugates (Yoo and Park, 2004b). To achieve targeting, folate was conjugated with 
TPGS for the PLGA-TPGS nanoparticles formulation of DOX, which can also be 




  68 
 5.2 Results and Discussion 
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Figure 5-1 1 H NMR spectrum of PLGA-TPGS copolymer. 
 
The structure of the synthesized PLGA-TPGS copolymer was detected and verified by 
1H NMR (Fig. 5-1). The Mn of the PLGA-TPGS copolymer and the component ratio 
of lactide:glycolide:TPGS was found to be 11,900 and 60:27:13, respectively, which 
were determined by using the ratio among the peak areas at 3.60 (-CH2 protons of 
PEO part of TPGS), 4.87 (-CH2 proton of PGA) and 5.21 ppm (-CH proton of PLA). 
After the PLGA-TPGS copolymer had successfully been synthesized, the amine-
terminated doxorubicin was covalently attached to the hydroxyl group of PLGA-
TPGS via a carbamate linkage by using p-nitrophenyl chroformate (NPC). The DOX 
content in the conjugate was determined to be 2.96% (weight %) by the microplate 
reader. Due to the small amount of DOX conjugated to the copolymer, the signal of 
DOX in the DOX-PLGA-TPGS conjugate was too weak to be detected by 1H NMR. 
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 The DOX-PLGA-TPGS conjugate was hence characterized by FT-IR (υ -OH, -NH: 
3300-3500 cm-1, υ C=O ester: 1735 cm-1, υ C=O amidic: 1645 cm-1). 
 
TPGS-FOL was synthesized by coupling the reaction between TPGS-NHS and FOL-
NH2 as schematized in Fig. 3-1. Before the coupling reaction, TPGS-NHS was 
synthesized by using glutaric acid as a linker between TPGS and N-
hydroxysuccinimide (NHS). The hydroxyl-terminated TPGS reacted with the 
carboxylic group of glutaric acid via ester bond formation. Next, another “free” 
carboxylic group of glutaric acid reacted with NHS to produce TPGS-NHS. On the 
other hand, folate was aminated with pyridine by DCC/NHS chemistry. It is believed 
that this reaction step will occur mainly at the γ-carboxylic group than the α-
carboxylic group of folate due to its higher reactivity (Wang et al., 1996; Wang et al., 
1997). 1H NMR spectroscopy measurements were carried out to identify the 
conjugation of folate onto TPGS. The spectrum of folate (Fig. 5-2(a)) exhibits typical 
peaks of folate at 1.85-2.10 ppm (β-CH2 of glutamic acid), 2.30 ppm (γ-CH2 of 
glutamic acid), 6.62 and 7.61 ppm (aromatic protons), 8.1 ppm (aliphatic amide 
proton), and 8.6 ppm (pteridine proton). The peaks at 2.50 and 3.30 ppm should be 
ignored as they are corresponding to DMSO and H2O peak respectively. The spectrum 
of TPGS (Fig. 5-2(b)) exhibits an intense peak at 3.65 ppm, which is the characteristic 
of methylene protons of PEO part in TPGS. The spectrum of TPGS-FOL in Fig. 5-
2(c) contains signals originating from both folate and TPGS, but with relatively much 
weaker intensity for the signals of folate. This probably due to the small molecular 
weight of folate (441 kD) compared to that of TPGS (1,542 kD).  








Fig. 5-2 1 H NMR spectra of (a) FOL, (b) TPGS and (c) TPGS-FOL (the insert shows 
a higher magnification of the region between 6 to 9 ppm). 
 
 
5.2.2 Characterization of DOX-loaded nanoparticles 
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In the nanoparticle fabrication process, DOX was deprotonated by adding an excess 
amount of TEA to become hydrophobic. It is done because hydrophobic DOX tends to 
be more easily entrapped in the core of hydrophobic matrix materials of the 
nanoparticles than hydrophilic salt form of DOX·HCl (Yoo and Park, 2004a). Brigger 
et al (2004) found that DOX was mainly distributed on the surface of nanoparticles 
and 90% of the formulated drug was released after 2 h when DOX was formulated in 
nanoparticles as hydrophilic salt form. In our nanoparticle formulation, DOX was 
entrapped in the nanoparticle matrix both in the physical hydrophobic form and in the 
PLGA-TPGS conjugate form. It has been reported that the π-π interaction (non-
covalent interaction between organic compounds containing aromatic rings) between 
the planar anthraycline ring structures of DOX molecules would be in favor of the 
dimerization of DOX molecules (Kataoka et al., 2000). Thus, it is very likely that the 
 terminally conjugated DOX in our PLGA-TPGS conjugate would interact and 
stabilize the physically-entrapped DOX. In our experiment, TPGS-FOL was blended 
with DOX-PLGA-TPGS at various ratios to investigate the targeting behavior of the 
drug-loaded nanoparticles. Folate moiety of TPGS-FOL is expected to be oriented 
outside towards aqueous phase, while leaving the physically entrapped DOX and 
chemically conjugated DOX in the core of the nanoparticles as schematically 
postulated in Fig. 5-3.  
 
DOX        PLGA       TPGS
FOL   TPGS
DOX-loaded TPGS-FOL/DOX-PLGA-TPGS NPs  
Fig. 5-3. Schematic representation of DOX-loaded nanoparticles of the DOX-PLGA-
TPGS and TPGS-FOL blend. 
 
 
The characteristics of the DOX-loaded nanoparticles are shown in Table 5-1. The drug 
loadings are found to be in the range of 2.77- 3.97%. The drug loading of the 
nanoparticles of TPGS-FOL component in the blends was found higher than that of 
the nanoparticles without TPGS-FOL component in the blend, which may be due to 
the TPGS effect. TPGS has shown to be a more effective emulsifier or additive than 
others in preparation of nanoparticles/microparticles because of its high emulsification 
efficiency and drug entrapment efficiency (Mu and Feng, 2002; 2003; 2005). In this 
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 study, we thus use the blends of TPGS-FOL with DOX-PLGA-TPGS as the 
nanoparticle matrix materials to formulate DOX for targeted chemotherapy. This idea 
was proved by the enhanced drug encapsulation efficiency (EE) achieved by the 
TPGS-FOL nanoparticles in comparison with that of 0% TPGS-FOL nanoparticles. 
However, too much TPGS-FOL component was found not to be in favor of this effect. 
When more TPGS-FOL was involved in the nanoparticle matrix, the nanoparticle 
would become more hydrophilic, and hence may lead to more drug to be washed away 
during the nanoparticle preparation process. The lower EE of 50% TPGS-FOL 
nanoparticles compared with 33% TPGS-FOL nanoparticles may be related to the 
hydrophilicity and small molecular weight of TPGS-FOL. 
 
Table 5-1. Characteristics of DOX-loaded nanoparticles of the TPGS-FOL and  
DOX-PLGA-TPGS blends 
 





b (%) Particle size (nm) 
0% TPGS-FOL 
nanoparticles 2 2.96 3.97±0.24 80.0±4.4 359±10 
20% TPGS-FOL 
nanoparticles 2 2.37 3.58±0.06 81.9±3.5 353±11 
33% TPGS-FOL 
nanoparticles 2 1.98 3.39±0.14 85.2±3.7 342±8 
50% TPGS-FOL 
nanoparticles 2 1.47 2.77±0.11 79.8±3.1 324±5 
 
a 0%, 20%, 33% and 50% TPGS-FOL nanoparticles stand for the nanoparticles of 0%, 20%, 33% and 50% (wt%) 
of TPGS-FOL in the blends of DOX-PLGA-TPGS and TPGS-FOL, respectively. 
b Drug encapsulation efficiency (EE) = (amount of drug in nanoparticles/amount of drug in feed) × 100 
 
 
The surface morphology of the TPGS-FOL nanoparticles was observed with a field 
emission scanning electron microscope and the images are shown in Fig. 5-4. The 
fabricated nanoparticles exhibited spherical shape with size of around 350 nm. 
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 (Park et al., 2005a). The N1s percentage was found increased with increasing of 
TPGS-FOL percentage in the nanoparticles fabrication. The N1s XPS data hence 
illustrated that TPGS-FOL was coated on the surface of the nanoparticles, whereby 
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Fig. 5-5 The XPS wide scan spectra of the DOX-loaded 0%, 20%, 33% and 50% 




5.2.4 In vitro drug release 
Fig. 5-6 shows the in vitro release profiles of DOX from the nanoparticles, which 
exhibited a biphasic release pattern characterized by an initial burst of around 20% of 
the total entrapped DOX in the nanoparticles at 1 h, which was mainly due to the 
release of physically entrapped DOX. The initial burst is followed by a slow, 
sustained release and it is found that the drug release would become faster when more 
TPGS-FOL component is contained in the blend. After 30 days, 48.3±3.5%, 
50.3±1.3%, 52.1±2.7% and 65.1±1.5% of the entrapped drug was found to be released 
from the 0%, 20%, 33% and 50% of TPGS-FOL nanoparticles, respectively.  




























Fig. 5-6 In vitro DOX release profiles from the nanoparticles. 
 
 
The sustained release of DOX from the nanoparticles was attributed to the gradual 
hydrolysis of the chemically bound DOX to the conjugate (Yoo and Park, 2001). The 
faster drug release of DOX from the nanoparticles of more TPGS-FOL content in the 
blend matrix may be caused by the smaller molecular weight and the hydrophilicity of 
TPGS-FOL. With the increased TPGS-FOL content in the blend nanoparticle matrix, 
more TPGS-FOL would occupy the nanoparticle surface and hence facilitate the water 
uptake and permeation into the nanoparticles, thus resulting in a faster drug release. 
 
5.2.5 In vitro cytotoxicity  
To evaluate the cell cytotoxicity of the free DOX and the drug formulated in the 
nanoparticles, the breast cancer MCF-7 and the brain cancer C6 cell lines were 
utilized as in vitro model. Fig. 5-7 shows the MCF-7 and C6 cell viability of the free 
DOX and the drug formulated in the nanoparticles, which were determined by MTT 
assay. As the DOX concentration increased, the cell viability of cancer cells was 
decreased (or equivalently, the cell mortality increased). DOX-loaded 0% TPGS-FOL 
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 nanoparticles exhibited comparable cytotoxicity to the free DOX against MCF-7 and 
C6 cells. The cell viability was found to decrease with the increase of TPGS-FOL 
content in the nanoparticles, as shown in Fig. 5-7. The MCF-7 cell viability was 
decreased from 50.8±8.1% for 0% of TPGS-FOL to 38.2±0.3%, 35.8±4.2%, and 
8.2±1.6% for 20%, 33% and 50% of TPGS-FOL nanoparticles, respectively, after 
incubation of the nanoparticles suspension at 100 µM (p<0.05, n=6). Similarly, the C6 
cell viability was found to be 56.5±0.7% for free DOX and 49.6±1.5% for 0% TPGS-
FOL nanoparticles, which are comparable each other. It is then decreased to 
41.3±1.7%, 36.5±1.3% and 30.6±4.6% for 20%, 33% and 50% of TPGS-FOL 
nanoparticles, respectively (p<0.05, n=6). The enhanced in vitro cytotoxicity of 
TPGS-FOL nanoparticles for both of MCF-7 and C6 cells could imply successful 
targeting effects of TPGS-FOL nanoparticles to the cancer cells with overexpression 
of the FOL receptors. 
 
The IC50 values of the free DOX and the nanoparticle formulation were summarized in 
Table 5-2. The IC50 values for both of MCF-7 cells and C6 cells were found to be 
dependent on the amount of the TPGS-FOL content in the nanoparticles. DOX-loaded 
nanoparticles with 50% TPGS-FOL significantly decreased the IC50 values compared 
with the free drug, 43.7±11.8 µM vs. 19.4±5.2 µM for MCF-7 cells and >100 µM vs. 
3.3±1.7 µM for C6 cells after incubated 24 h (p<0.05, n=3). These results suggest that 
TPGS-FOL content in the nanoparticle matrix effectively decreased the in vitro caner 
cell viability of the drug formulated in the nanoparticles, which could imply the 
targeting effects of the nanoparticle formulation in vivo.  
 









































Fig. 5-7 (a) MCF-7 and (b) C6 cancer cell
in the  0%, 20%, 33% and 50% TPGS-FO
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 5.2.6 In vitro Cellular uptake of nanoparticles     
To evaluate the targeting effect of the nanoparticles on cancer cells, the cellular uptake 
of the free drug and the 0% and 50% TPGS-FOL nanoparticles by MCF-7 and C6 
cells were investigated. Fig. 5-8 shows the (a) MCF-7 and (b) C6 cell uptake 
efficiency of DOX in the free drug form and that formulated in the nanoparticles at 
0.5, 1.5, 4.0 and 6.0 h cell culture. The DOX concentration for the nanoparticle 
formulation in the culture medium was adjusted to be the same as that of free DOX, 
which was 4.5 µg/mL. It can be seen from Fig. 5-7 that DOX-loaded nanoparticles 
exhibited much higher cellular uptake efficiency than the free drug, which may be 
attributed to the multi-drug resistance (MDR) effect for the free drug, since DOX is a 
substrate of P-glycoproteins which are rich in the cancer cells.  
 
The nanoparticles of 50% of TPGS-FOL blend component showed enhanced MCF-7 
cell uptake of the drug up to 1.5-, 1.5-, 1.4-, 1.3-fold and C6 cell uptake of the drug up 
to 1.7-, 1.6-, 1.3-, 1.2-fold in comparison with the nanoparticles with no TPGS-FOL 
after 0.5, 1.5, 4 and 6 h cell culture, respectively. The enhanced cellular uptake of the 
drug formulated in the 50% TPGS-FOL nanoparticles compared with that of 0% 
TPGS-FOL nanoparticles could be attributed to the folate-receptor mediated 
endocytosis. Moreover, Fig. 5-8 also demonstrates that the enhanced cellular uptake 
efficiency of the nanoparticles becomes more significant with the increase of the cell 
culture time. Our findings agree with the previously reported results in literature (Mo 
and Lim, 2005). 
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 nanoparticles with no TPGS-FOL component (Fig 5-9(b)), the red fluorescence was 
observed probably in endosomes. In contrast, the nanoparticles with 50% TPGS-FOL 
in the blend matrix (Fig. 5-9(c)) showed intense red fluorescence around the nucleus 
and a broad distribution of fluorescence in the cytosol. This observation thus 
demonstrated that the FOL-decorated nanoparticles do have targeting effects for DOX 
delivery to the C6 cancer cells, suggesting that the FOL-decorated nanoparticles were 
endocytosed via a folate receptor-mediated mechanism. In addition, some red 
fluorescence can also be observed in the nucleus when the cells were incubated with 
the FOL-decorated nanoparticles. This might be due to a very small amount of the 
physically entrapped DOX that had been released from the nanoparticles inside the 
cells and then reached the nucleus. This observation tallies with what we observed 
before in the in vitro drug release study, where the drug release from the 50% TPGS-
FOL nanoparticles was much faster than that of the nanoparticles with no TPGS-FOL 







Fig. 5-9 CLSM of C6 cancer cells incubated with DOX (a) in free form, or formulated  
(b) in the nanoparticles of no TPGS-FOL component in the blend matrix (i.e. the 0%  
TPGS-FOL nanoparticles) or (c) in the 50% TPGS-FOL nanoparticles for 3 h at 37 ºC. 
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 5.3 Conclusion 
In this study, we synthesized and characterized novel TPGS-FOL and DOX-PLGA-
TPGS conjugates. Nanoparticles of the TPGS-FOL and DOX-PLGA-TPGS blends 
with various component ratios were then prepared for targeted drug delivery with 
doxorubicin as a prototype drug. The drug-loaded nanoparticles showed significant in 
vitro targeting effects for MCF-7 breast cancer cells and C6 brain tumor cells, which 
resulted in higher cytotoxicity and enhanced cellular uptake in comparison with the 
free drug.  Our results suggest that the folate-decorated nanoparticles of the TPGS-
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 Chapter 6  CONCLUSIONS AND SUGGESTIONS 
FOR FUTURE WORK 
 
6.1 Conclusions 
This thesis describes the synthesis and characterization of (i) BSA-loaded PLA-TPGS 
nanoparticles from PLA-TPGS copolymers using double emulsion method; (ii) 
Folate-decorated PLGA-TPGS nanoparticles from a blend of DOX-PLGA-TPGS 
conjugate and TPGS-FOL conjugate using solvent extraction/evaporation method. 
The feasibility of PLA-TPGS nanoparticles for protein drug delivery and folate–
decorated PLGA-TPGS nanoparticles for targeted drug delivery were established and 
optimized by using BSA as a model protein and doxorubicin as prototype, 
respectively. 
 
The properties of BSA-loaded PLA-TPGS nanoparticles can be engineered by 
material and process parameters. Effect of various formulation variables such as 
TPGS content of PLA-TPGS copolymer and BSA loading on particle size, protein 
encapsulation efficiency, in vitro release profile and nanoparticle degradation were 
investigated and optimized. The introduction of amphiphilic TPGS domain in 
copolymer and the presence of BSA within nanoparticles show critical influence on in 
vitro protein release profile and nanoparticle degradation rate as compared to that of 
PLGA. PLA-TPGS nanoparticles appear to be able to offer an advantage over PLGA 
nanoparticles, including the generation of a more stabilizing environment for protein. 
Cellular uptake experiment further illustrates the potential of PLA-TPGS 
nanoparticles as protein and peptide drug carriers. 
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 Folate-decorated PLGA-TPGS nanoparticles composed of various blend ratio of 
DOX-PLGA-TPGS conjugate to TPGS-FOL conjugate were prepared to act as a novel 
drug carrier for doxorubicin. TPGS-FOL conjugate plays dual role as both the 
surfactant and the targeting moiety in this methodology. The DOX-PLGA-
TPGS/TPGS-FOL nanoparticles were surrounded with a protective TPGS while 
exposing folate moiety for interactions with folate receptor. Various blend ratios of 
both conjugates were found to have minima effect on particle size and drug EE, but 
have significant effect on in vitro cellular uptake and cell viability results. The 
enhanced cellular uptake and higher cell cytotoxicity of folate-decorated nanoparticles 
compared to that of nanoparticles without folate targeting moiety further illustrate that 




6.2 Suggestions for future work 
Some encouraging preliminary results have been obtained from our studies of PLA-
TPGS nanoparticles for controlled oral delivery of peptides and proteins with BSA as 
a model protein. However, as mentioned above, BSA is just a model protein in our 
studies. Therefore, further studies of PLA-TPGS nanoparticles for entrapment of a 
therapeutically active protein, such as tetanus toxoid, insulin, recombinant human 
growth (rhGH) or calcitonin etc are suggested to carry out. The pharmacokinetics of 
protein-loaded nanoparticles should be studied. The development of in vitro to in vivo 
correlation for protein release from PLA-TPGS nanoparticles should be strengthened. 
We hope that some day, protein will be taken orally in the form of PLA-TPGS 
nanoparticles. 
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 Our studies have demonstrated that folate-decorated PLGA-TPGS nanoparticles 
containing doxorubicin could be a potentially useful delivery system for targeting 
folate-receptor-positive cancer cells. Further studies are hence recommended to test 
their applicability in vivo. In vivo experiment employing a human tumor xenograft 
animal should be performed to confirm the superior anticancer effect of this new drug 
delivery system. This work can be further extended to develop multifunctional 
nanoparticles for targeting, imaging (or diagnosing), therapy delivery and result-
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